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CHAPTER 1 
 
 
 
Overview: Background and Significance 
 
 
1.1 Antidepressant and Older Adults 
Antidepressants are medications used to treat depressive and other affective/mood 
disorders, such as anxiety and bipolar disorders.1,2 Antidepressant use increased nearly 
400% from 1988-1994 to 2005-2008 in all ages,3 and antidepressants were now one of 
top three most commonly prescribed medications in the U.S.,4,5 accounting for more than 
260 million prescriptions each year.5 In addition, antidepressants are the ninth most costly 
medications during the period of 2007-2011 in the U.S., accounting for approximately 
$20 billion in sales in 2011.6 Approximately 11% of non-institutionalized U.S. citizens 
ages 12 and over take antidepressants, and 60% of them have taken antidepressants for 
two years or longer.7 Furthermore, antidepressants are disproportionately distributed by 
age, such that adults ages 40 or older are more likely to take antidepressants than their 
younger counterparts.7  
 Approximately 15-20% of older adults experience depression in their late life 
stage, affecting 7 million older adults ages 65 and over in the U.S.8,9 Late-life depression 
is a significant public health concern, as depression can increase burden of comorbid 
conditions (e.g., dementia, diabetes and cardiovascular disease), disability, and mortality 
among older adults.10 Unfortunately, older adults are often under-diagnosed and/or under-
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treated for depression.9 When used safely, antidepressants can be an effective 
pharmacological intervention to treat late-life depression in older adults. 
 
1.2. Potentially Inappropriate Antidepressant Use 
Despite the increasing rate of antidepressant use in the general population lately, 
relatively little is known about the prevalence of and possible reasons for potentially 
inappropriate use of antidepressants among older adults in office-based outpatient 
settings. Potentially inappropriate medications are not only continuously prescribed,11-13 
but also remain problematic as they are associated with (1) potentially avoidable 
healthcare expenditures,14-16 estimated to be $7.2 billion in a 2001-2002 study,16 and (2) 
increased hospitalization,17-21 morbidity22 and mortality20 rates in older adults. Other 
studies, however, suggest mixed results (e.g., no association between potentially 
inappropriate antidepressant use and mortality).23-26 Because avoiding, or reducing, 
potentially inappropriate use of any medication is an effective strategy to reduce adverse 
drug events and other medication errors,11,27 the incidence and/or prevalence of 
potentially inappropriate medication use may be used as one of the quality of care 
indicators among older adults in office-based antidepressant-related visits. 
In the U.S., a list of potentially inappropriate medications was developed by Beers 
and his colleagues (hereafter referred to as Beers Criteria) for older adults living in 
nursing homes in 1991.28 The Beers Criteria were updated over time11,29,30 and are now 
applicable to older adults in all settings of geriatric care.11 The most up-to-date version of 
Beers Criteria in 2012 is explicit (i.e., criterion-based) rather than implicit (i.e., judgment-
based), as it is based on systematic reviews of clinical studies and expert opinions using 
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consensus techniques.11 In particular, it is supported by the American Geriatrics Society 
(AGS) and Centers for Medicare and Medicaid Services (CMS) among other interest 
groups.11 The Beers Criteria are commonly known as the drug-to-avoid criteria (i.e., mis-
prescribing as potentially inappropriate medication use), as they focus on the choice of 
drug and drug interaction. The Beers Criteria are also shown to be appropriate and 
applicable for research driven by large databases.11,12 Hereafter, the definition of 
potentially inappropriate antidepressant use is based on Beers Criteria. 
 
1.3. Epidemiology of Potentially Inappropriate Antidepressant Prescriptions  
 Monitoring national trends of overall and potentially inappropriate antidepressant 
prescriptions is important for two reasons. First, as part of the Patient Protection and 
Affordable Care Act (ACA) of 2010, the Triple Aim has been selected as a national 
strategy to resolve health care issues.31,32 When applied to older adults who are prescribed 
with antidepressants in office-based outpatient visits, the Triple Aim may consist of: (1) 
improving patient experience of care (e.g., providing value-based care); (2) improving the 
health of populations (e.g., reducing adverse drug events); and (3) reducing costs (e.g., 
reducing avoidable health care expenditures). A descriptive study of patterns for overall 
and potentially inappropriate antidepressant prescriptions at the national level can be 
informative as an initial step towards the Triple Aim, as it can further shape future 
research and practice guidance to achieve the goals of the Triple Aim for older adults who 
are prescribed with antidepressants in their office-based outpatient visits.  
Second, continuous quality improvement (CQI)33 and other quality of care 
improvement programs in office-based outpatient care often focus on (1) improving 
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patient satisfaction with visits; (2) improving continuity of care among providers; and (3) 
other quality of care indicators (e.g., improving delivery of medical practice) by 
identifying and reducing unnecessary, avoidable procedures.34 By understanding and 
using the national trend of potentially inappropriate antidepressant prescriptions as a 
benchmark, health care providers can bring clinical efforts on quality assurance and 
performance improvement in their practice related to antidepressant use among older 
adults in office-based outpatient visits. 
 Despite the importance of understanding the national trends of overall and 
potentially inappropriate antidepressant prescriptions descriptively, existing studies have 
several limitations. For example, previous studies5,35 focused on the individual level 
rather than at the level of office-based outpatient visit; while they are informative 
understanding individual factors, they rarely convey information about physician- and/or 
practice-related factors. Other studies systematically excluded the older adult 
population,36 were conducted outside the U.S.,37 or are outdated.37 In light of updated 
2012 Beers Criteria and potential demographic shifts (i.e., aging America), an updated 
descriptive study of national trends for overall and potentially inappropriate 
antidepressant prescriptions among older adults in their office-based outpatient visits is 
needed.      
 
1.4. Impact of Recent Policy Recommendation on Potentially Inappropriate 
Antidepressant Prescriptions 
 Despite the high prevalence (15-20%) of depression in older adults, depression 
and other related mood disorders (e.g., dysthymia) are often under-diagnosed and under-
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treated.9 While adults with depression are not likely to make psychiatry-related visits, 
they still seek care in general or other specialty visits, making “these visits particularly 
important opportunities to detect and initiate treatment of depression”38(p. 279) In light of 
providing care for depression in primary care and other specialty visits, screening for 
depression has become a “prominent component of the “detect—treat—improve” 
paradigm for undetected depression” since the mid-1990s.38 (p.280)  
 To provide systematic, comprehensive evidence for effectiveness and 
recommendations regarding depression screening, the U.S. Preventive Services Task 
Force (USPSTF) created a task force group on screening for depression in adults in late 
1990s. The USPSTF is “an independent group of national experts in prevention and 
evidence-based medicine that works to improve the health of all Americans by making 
evidence-based recommendations about clinical preventive services such as screenings, 
counseling services, or preventive medications.”39 The USPSTF is supported by the 
Agency for Healthcare Research and Quality (AHRQ), as part of the U.S. Department of 
Health and Human Services. Currently, there are more than 40 standardized 
recommended practice guidelines (e.g., depression screening in adults and mammography 
for women) disseminated by the USPSTF.   
In 2009, the USPSTF disseminated its practice recommendation that depression 
screening should be provided in eligible older adults ages 65 and over to “ensure accurate 
diagnosis, effective treatment and appropriate follow-up” related to depression and other 
mental health conditions. 40,41 While there are validated depression screening instruments 
(e.g., Geriatric Depression Scale (GDS) and Patient Health Questionnaire 9 (PHQ-9)), the 
USPSTF does not specify which depression screening instruments should be used.40 
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In existing literature, there are several studies that assess the policy impacts of 
recent USPSTF guidelines (e.g., mammography use42 and pediatric urinalysis43). 
However, no study has yet assessed the impact of the 2009 depression screening 
recommendation. It is of question if the 2009 depression screening recommendation had 
a differential impact on diagnosing depression and other mental health conditions, as well 
as prescribing overall and potentially inappropriate antidepressants. Findings can help 
determine if the 2009 USPSTF depression screening recommendation has been beneficial 
in detecting and treating older adults with depression and other related mood disorders 
during their office-based outpatient visits. Findings may also suggest that future research 
may be needed to assess spill-over effects and their magnitudes of the 2009 USPSTF 
depression screening recommendation regarding the aforementioned outcomes as well as 
other important outcomes, such as patient-reported outcomes (e.g., health-related quality 
of life).   
 
1.5. Depression Screening and Potentially Inappropriate Antidepressant Prescriptions 
in Clinical Practice  
 While depression screening is recommended by the USPSTF and other interest 
groups, such as the American College of Preventive Medicine (ACPM)44 and American 
Heart Association (AHA),45 there is a consistent controversy about the use of depression 
screening in clinical practice. Most randomized controlled trial (RCT) studies found no 
association between depression screening and patient outcomes (e.g., depressive 
symptoms).46,47 When considering detection and treatment for depression and other 
related mental health conditions as intermediate outcomes, the role of depression 
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screening is still mixed in RCTs.48 Based solely on findings from such RCTs, the 
Canadian Task Force on Preventive Health Care (CTFPHC)—the Canadian version of 
USPSTF—is opposed to recommend depression screening in clinical practice in 
Canada.49 
However, these RCT studies employed relatively homogeneous, small study 
samples and systematically excluded older adults. Furthermore, as one study suggests, 
findings from depression-related RCTs are not representative of usual medical settings.50 
Thus, generalizability is questionable. Because of limited external validity from RCTs, 
greater external validity is needed using population-based observational studies. To my 
knowledge, there is only one population-based observational study,51 which provides a 
promising evidence that depression screening may improve appropriate antidepressant 
use in office-based outpatient visits. The same study, however, only used overall 
antidepressant prescriptions as an outcome among the general population, and did not 
consider potentially inappropriate prescriptions among older adults.  
A deeper understanding of the relationship between depression screening and 
potentially inappropriate antidepressant prescriptions is needed among older adults in 
their office-based outpatient visits. Findings may inform whether depression screening is 
consistent with the USPSTF recommendation and should be implemented in clinical 
practice for this specific elderly population group in the U.S.     
 
1.6. Specific Aims 
To address current gaps in research, the goals of proposed study are: (1) to 
explore patterns of overall and potentially inappropriate antidepressant prescriptions; (2) 
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to examine a policy impact of depression screening on (i) diagnosing depression and 
other mental health conditions and (ii) prescribing overall and potentially inappropriate 
antidepressant prescriptions; and (3) to determine the effect of depression screening in 
clinical practice among older adults in office-based outpatient settings. Using National 
Ambulatory Medical Care Survey (NAMCS) data from 2002 to 2012, which nationally 
represent office-based outpatient visits of all ages, the proposed dissertation project has 
the three following specific aims: 
 
Aim #1:  To describe prevalence rates (%) of (1) overall antidepressant prescriptions and 
(2) potentially inappropriate antidepressant prescriptions, and to understand factors 
associated with them among older adults ages 65 and over in office-based outpatient 
visits.  
1.1. Overall antidepressant prescriptions 
1.1.1. What is the prevalence of office-based outpatient visits that had any 
antidepressant prescription among older adults ages 65 and over in their 
office-base outpatient visits by year from 2002-2012? 
1.1.2. What is the distribution of socio-demographic and health-related 
characteristics by the status of any antidepressant prescription among older 
adults ages 65 and over in their office-base outpatient visits by year from 2002 
to 2012? 
1.1.3. Which socio-demographic and health-related characteristics are associated 
with office-based outpatient visits that had any antidepressant prescription 
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among older adults ages 65 and over in their office-base outpatient visits by 
year from 2002 to 2012? 
1.2. Potentially inappropriate antidepressant prescriptions using Beers Criteria 
1.2.1. Using Beers Criteria, what is the prevalence of office-based outpatient visits 
that had potentially inappropriate antidepressant prescriptions among older 
adults ages 65 and over in their office-base outpatient visits by year from 2002 
to 2012? 
1.2.2. Using Beers Criteria, what is the distribution of socio-demographic and 
health-related characteristics by the status of potentially inappropriate 
antidepressant prescriptions among older adults ages 65 and over in their 
office-base outpatient visits by year from 2002 to 2012?  
1.2.3. Using Beers Criteria, which socio-demographic and health-related 
characteristics are associated with office-based outpatient visits that had 
potentially inappropriate antidepressant prescriptions among older adults ages 
65 and over in their office-base outpatient visits by year from 2002 to 2012? 
For aim #1.2, Beers Criteria will be operationalized using: (1) the 2002 version; 
(2) the 2012 version; Operational definitions and rationale will be further described in the 
methods section. 
 
Aim #2:  To examine the policy impact of the 2009 U.S. Preventive Services Task Force 
(USPSTF) depression screening recommendation on (1) the diagnosis of depression; (2) 
the diagnosis of mental health conditions other than depression; and (3) overall 
antidepressant prescriptions; and (4) potentially inappropriate antidepressant 
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prescriptions between pre- (2006-2008) and post- (2010-2012) periods among older 
adults ages 65 and over in office-based outpatient visits.  
2.1. Diagnosis of depression 
2.1.1. Did the rate of diagnosis of depression increase by depression screening status 
after implementation of the 2009 USPSTF depression screening 
recommendation among older adults ages 65 and over in office-based 
outpatient visits? 
2.1.2. Was there a differential impact of the 2009 USPSTF depression screening 
recommendation on the diagnosis of depression by depression screening status 
among older adults ages 65 and over in office-based outpatient visits? 
2.2. Diagnosis of mental health conditions other than depression 
2.2.1. Did the rate of diagnosis of mental health conditions other than depression 
increase by depression screening status after implementation of the 2009 
USPSTF depression screening recommendation among older adults ages 65 
and over in office-based outpatient visits? 
2.2.2. Was there a differential impact of the 2009 USPSTF depression screening 
recommendation on the diagnosis of mental health conditions other than 
depression by depression screening status among older adults ages 65 and 
over in office-based outpatient visits? 
2.3. Overall antidepressant prescriptions 
2.3.1. Did the prevalence (%) of overall antidepressant prescriptions increase by 
depression screening status after implementation of the 2009 USPSTF 
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depression screening recommendation among older adults ages 65 and over in 
office-based outpatient visits? 
2.3.2. Was there a differential impact of the 2009 USPSTF depression screening 
recommendation on the prevalence (%) of overall antidepressant prescriptions 
by depression screening status among older adults ages 65 and over in office-
based outpatient visits? 
2.4. Potentially inappropriate antidepressant prescriptions using Beers Criteria 
2.4.1. Did the prevalence (%) of potentially inappropriate antidepressant 
prescriptions increase by depression screening status after implementation of 
the 2009 USPSTF depression screening recommendation among older adults 
ages 65 and over in office-based outpatient visits? 
2.4.2. Was there a differential impact of the 2009 USPSTF depression screening 
recommendation on the prevalence (%) of potentially inappropriate 
antidepressant prescriptions by depression screening status among older adults 
ages 65 and over in office-based outpatient visits? 
In aim #2.4, the version(s) of Beers Criteria will be considered based on findings 
from aim #1.2.   
 
Aim #3:  To explore a potential effect of depression screening on (1) the diagnosis of 
depression; (2) the diagnosis of mental health conditions other than depression; (3) 
overall antidepressant prescriptions; and (4) potentially inappropriate antidepressant 
prescriptions in the post-period (2010-2012) of the 2009 USPSTF depression screening 
recommendation among older adults ages 65 and over in office-based outpatient visits.  
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3.1. Diagnosis of depression 
3.1.1. Does depression screening have an effect on the diagnosis of depression 
among older adults ages 65 and over in office-based outpatient visits? 
3.2. Diagnosis of mental health conditions other than depression 
3.2.1. Does depression screening have an effect on the diagnosis of mental health 
conditions other than depression among older adults ages 65 and over in 
office-based outpatient visits? 
3.3. Overall antidepressant prescriptions 
3.3.1. Does depression screening have an effect on the overall antidepressant 
prescriptions among older adults ages 65 and over in office-based outpatient 
visits? 
3.4. Potentially inappropriate antidepressant prescriptions using Beers Criteria 
3.4.1. Does depression screening have an effect on the potentially inappropriate 
antidepressant prescriptions among older adults ages 65 and over in office-
based outpatient visits? 
 
In order to address these aims, data from the NAMCS will be used. The NAMCS 
data present a unique opportunity to explore issues surrounding overall and potentially 
inappropriate antidepressant prescriptions among a nationally-representative sample of 
U.S. older adults in office-based outpatient settings. Overall, the proposed study has the 
following expected outcomes: First, I will estimate the prevalence (%) of overall and 
potentially inappropriate antidepressant prescriptions by year, and factors associated with 
them from 2002 to 2012. The findings will provide a deeper understanding of factors 
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driving the national trend of antidepressant-related prescribing patterns. Second, I will 
investigate whether a recent policy recommendation (i.e., depression screening) had any 
impact on (1) diagnosing mental health conditions, including depression, and (2) 
prescribing overall and potentially inappropriate antidepressants in older adults during 
their office-based outpatient visits. The findings will provide insights whether the policy 
recommendation has been beneficial for older adults who are often under-diagnosed and 
under-treated with depression and other related mood disorders. Third, I will determine 
whether depression screening—unlike findings from previous RCTs—should be provided 
to older adults in their office-based outpatient visits. Ultimately, this research project will 
bring positive impact by promoting clinical and policy efforts to improve patient safety in 
older adults who are prescribed with antidepressants in office-based outpatient settings.  
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CHAPTER 2 
 
 
 
Study Designs and Data Collection 
 
 
 
 
2.1. Data Source and Study Population 
 I used data from the 2002-2012 National Ambulatory Medical Care Survey 
(NAMCS), which is administrated by the National Center for Health Statistics (NCHS), 
Centers for Disease Control and Prevention (CDC).1 The NAMCS is an annual, cross-
sectional survey of visits to office-based physicians in outpatient settings. The NAMCS 
represents office-based outpatient care and provides reliable information about the 
provision and/or use of ambulatory medical care services in the United States.1  
 Using a multi-stage probability sampling design, data were collected from office-
based physicians. First, a probability sample of primary sampling units (PSUs) was 
drawn. A PSU consists of “a county, a group of counties, county equivalents (such as 
parishes and independent cities), towns, townships, minor civil divisions (for some PSUs 
in New England), or a metropolitan statistical area (MSA).”2(p. 9) In the second stage, a 
probability of sample of practicing physicians within chosen PSUs was drawn. These 
physicians are further stratified by specialty groups (e.g., general and family practice, and 
psychiatry) within each PSU. Finally, each physician was randomly selected to a 1-week 
reporting period; during this period, data for a systematic random sample of patient visits 
to the physician were abstracted. Data include patients’ socio-demographic characteristics 
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(e.g., age, sex, and race/ethnicity) and health-related information (e.g., comorbidity), as 
well as physician’s diagnoses, procedures and medications provided. 
The survey response rate varies from 58.3 to 70.4% (see Table 2.1) over the years. 
Of 90,472 visits (unweighted) for adults ages 65 and over in 2002-2012, I excluded 
observations with missing covariates (4.96%), leaving the final sample size of 85,987 
visits (unweighted) (see Table 2.1). Further details of the survey, including descriptions, 
questionnaires, sampling methodology and datasets, are publicly available on the 
NAMCS website.3 
 
Table 2.1. Study sample of office-based outpatient visits for adults ages 65 and older 
by year, NAMCS 2002-2012. 
Note: a) indicates that data are not available. 
 
 
2.2. Key Measures 
Antidepressant use: 
 Overall antidepressant prescriptions. Using the 2015 American Hospital 
Formulary Service (AHFS) Compendium,4 Wolters Kluwer’s Drug Facts and 
Comparisons,5 and previous studies,6-11 I identified prescribed antidepressant 
Year Survey response rate 
Study sample 
Unweighted sample Weighted visit 
2002 70.4% 7,451 224,380,087 
2003 66.9% 6,886 227,520,460 
2004 64.7% 7,086 233,991,068 
2005 61.5% 6,876 247,683,250 
2006 58.9% 7,451 229,837,453 
2007 61.6% 8,968 258,214,352 
2008 59.1% 7,211 256,135,092 
2009 62.1% 8,673 279,513,535 
2010 58.3% 8,156 258,976,010 
2011 -a) 8,247 255,736,330 
2012 -a) 21,714 247,633,504 
Total 58.3-70.4% (range) 98,719 247,238,286 
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medications using generic names (see Table 2.2). In 2002, up to six medications 
were recorded in each visit. From 2003-2010, up to eight medications were 
recorded in each visit, and the maximum number of medications recorded was 
increased to 12 in 2012. I included all antidepressant medications prescribed in 
the analytic sample to measure crude estimates. I created binary indicator 
variables for each generic name of antidepressants. For overall antidepressant 
prescriptions, I created a binary indicator (yes/no), aggregating the individual 
prescribed antidepressants. 
 Potentially inappropriate antidepressant prescriptions. For potentially 
inappropriate antidepressant prescriptions, I constructed three different binary 
indicator variables (yes/no): (1) the 2012 version of Beers Criteria (see Table 2.2 
for “independent of diagnosis” and Table 2.3 for “drug-disease or drug-syndrome 
interactions”); (2) the 2002 version of Beers Criteria (see Table 2.4 for details); 
and (3) the Beers Criteria contemporary to each year (i.e., the 2002 version for 
2002-2011 and the 2012 version for 2012).12,13  
o 2012 version: I used the 2012 version to look at the national trends of 
potentially inappropriate antidepressant prescriptions retrospectively. 
Using the 2012 version, which contains clinically rigorous, up-to-date 
recommendations, would give a sense of how changes in the recent 
guideline may have been affected the prevalence (%) of potentially 
inappropriate antidepressant prescriptions by year from 2002 to 2012 
among older adults ages 65 and over who had office-based outpatient 
visits. 
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o 2002 version: I also used the 2002 version in order to look at the national 
trends of potentially inappropriate antidepressant prescriptions 
prospectively since the earlier version of Beers Criteria was disseminated 
in 2002. Using the 2002 version, if the prevalence of potentially 
inappropriate antidepressant prescriptions decreased over time among 
antidepressant-related, office-based outpatient visits, it may be inferred 
that the Beers Criteria has been effectively used in clinical practice.  
o Version contemporary to each year: Finally, the Beers Criteria 
contemporary to each year (i.e., the 2002 version for 2002-2011 and the 
2012 version for 2012) were also used to further observe similarities or 
differences between 2002 and 2012 versions for potentially inappropriate 
antidepressant prescriptions. 
 
 Mental health conditions:  
 Mental health conditions. In aim #1, mental health conditions are one of 
covariates. Using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM), I identified mental health diagnoses that are 
clinically relevant and have significant burden to older adults as follow: (1) 
depressive disorders; (2) bipolar disorders; (3) schizophrenia; (4) anxiety 
disorders; (5) personality disorders; (6) delirium, dementias and other cognitive 
impairment; and (7) others. Table 2.5 lists the ICD-9-CM diagnostic codes 
included in each category.14 
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 Depression. For aims #2.1.1, 2.1.2, and 3.1.1, diagnosis of depression is a 
dependent variable. I constructed a binary indicator variable (yes/no) using the 
ICD-9-CM diagnostic codes (296.2 & 296.3) (see Table 2.5).  
 Mental health conditions other than depression. In aims #2.2.1, 2.2.2, and 3.2.1, 
diagnosis of mental health conditions other than depression is a dependent 
variable. Based on Table 2.5, I constructed a binary indicator variable (yes=any 
mental health condition diagnosed, except depression; no=otherwise).     
 
Screening/counseling:  
 Depression screening: In the “diagnostic and screening services section” of the 
NAMCS, depression screening is asked (yes/no) for the purpose of “early 
detection of health problems in asymptomatic individuals.”3 This binary variable, 
depression screening, is a key independent variable in aims #2 and 3. 
 Diet/nutrition education and counseling: Under the “health education ordered or 
provided section” of the NAMCS, physicians were asked if diet/nutrition 
education and counseling were provided (yes/no) to the patient. This is a key 
instrumental variable in aim #3. 
 Exercise education and counseling: Under the “health education ordered or 
provided section” of the NAMCS, physicians were asked if exercise education 
and counseling were provided (yes/no) to the patient. This is a key instrumental 
variable in aim #3. 
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Covariates: 
Based on (1) previous studies,6,9,10,15-28 (2) potential confounders related to 
research questions, and (3) availability in data, I selected a number of covariates to 
control for in the statistical analyses.  
 Socio-demographic characteristics: These include: (1) age (65-74; 74-85; 85+); 
(2) gender (male and female); (3) race/ethnicity (non-Hispanic White, non-
Hispanic Black, Hispanic, and other); (4) region (Northeast, Midwest, South, and 
West); and (5) primary source of payment (Private, Medicare, Medicaid, and 
others). 
 Health-related, clinical characteristics: These include: (1) reason for visit 
(acute/new problem, chronic problem, preventive care, pre-/post-surgery); (2) 
repeat of visits in the past 12 months; (3) physician specialty (primary care, 
psychiatry, and other specialties); (4) type of medical practice (solo/group 
practice vs. others); (5) metropolitan statistical area (MSA) status (yes/no); (6) 
provision of psychotherapy (yes/no); (7) time spent with doctor (minutes); (8) 
comorbid status (number of chronic conditions); and (9) polypharmacy (number 
of medications).  
 
Operationalization of each variable is further described in Table 2.6. In addition, 
Table 2.6 summarizes which variables are to be included in each specific aim. They are 
also in accord with the analytical plans, which would be described below.  
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2.3. Analytical Plans 
Aim #1: Aim #1 is a descriptive study and key statistical techniques include: univariate 
analysis (i.e., prevalence (%)), bivariate analysis (i.e., design-based F-statistics), and 
multivariate logistic regression analysis. A proposed analytical plan by each specific sub-
aim in aim #1 is described below (see Table 2.7.1). Selected variables for each analytical 
plan are summarized in Table 2.6. 
Table 2.7.1. Proposed analytical plan by specific aim #1 
Aim #1 Proposed analytical plan 
1.1.1.  Calculate the prevalence (%) of overall antidepressant prescriptions as 
follows: # of office-based outpatient visits with any antidepressant 
prescribed / # of all office-based outpatient visits among older adults by 
each year. 
1.1.2.  Conduct a bivariate analysis (i.e., a two-way tabulation) on each of 
socio-demographic and health-related characteristics (see table 2.6) by 
the status of overall antidepressant prescriptions. Design-based F-
statistics and p-value would be reported to observe significant, different 
patterns of each variable’s distribution by the status of overall 
antidepressant prescriptions. It would be conducted by each year. 
1.1.3.  Conduct a multivariate logistic regression analysis of the status of overall 
antidepressant prescriptions on socio-demographic and health-related 
characteristics (see table 2.6). 95% confidence interval and p-value of 
each regressor would be reported to see its significant relationship with 
the overall antidepressant prescriptions, holding other variables constant. 
1.2.1.  Calculate the prevalence (%) of potentially inappropriate antidepressant 
prescriptions as follows: # of office-based outpatient visits with 
potentially inappropriate antidepressant prescribed / # of all office-based 
outpatient visits among older adults by each year. 
1.2.2.  Conduct a bivariate analysis (i.e., a two-way tabulation) on each of 
socio-demographic and health-related characteristics (see table 2.6) by 
the status of potentially inappropriate antidepressant prescriptions. 
Design-based F-statistics and p-value would be reported to observe 
significant, different patterns of each variable’s distribution by the status 
of potentially inappropriate antidepressant prescriptions. It would be 
conducted by each year. 
1.2.3.  Conduct a multivariate logistic regression analysis of the status of 
potentially inappropriate antidepressant prescriptions on socio-
demographic and health-related characteristics (see table 2.6). 95% 
confidence interval and p-value of each regressor would be reported to 
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Aim #1 Proposed analytical plan 
see its significant relationship with the potentially inappropriate 
antidepressant prescriptions, holding other variables constant. 
 
 
Aim #2: Aim #2 focuses on policy evaluation and difference-in-differences (DID) 
approach is the key statistical technique to be used. The DID method is appropriate, as it 
compares treatment (i.e., those who received depression screening) and control (i.e., 
those who did not receive depression screening) groups in terms of outcome changes 
(e.g., overall antidepressant prescriptions) over time (i.e., pre-/post-intervention).29 The 
key assumption when applying the DID method is that unobserved selection bias—or 
unobserved heterogeneity—in participation (i.e., depression screening) may present, but 
is time-invariant.29 Then, such unobserved selection bias can be canceled out by using the 
DID method, and the impact of 2009 USPSTF depression screening recommendation can 
be measured. A proposed analytical plan by each specific sub-aim in aim #2 is described 
below (see Table 2.7.2). Selected variables for each analytical plan are summarized in 
Table 2.6. 
Table 2.7.2. Proposed analytical plan by specific aim #2 
Aim #2 Proposed analytical plan 
2.1.1.  Calculate the prevalence (%) of depression diagnosed by (1) depression 
screening status and (2) by pre- (2006-2008) and post- (2010-2012) 
periods. 
 Descriptively observe the patterns using bivariate analyses (i.e., a two-
way tabulation) of these key variables. Design-based F-statistics and p-
value would be reported for each pattern.  
2.1.2.  Conduct a multivariate logistic regression analysis of the depression 
diagnosed on depression screening status, time indicator (pre/post), and 
the interaction of depression screening status and time indicator, while 
controlling for all other socio-demographic and health-related 
characteristics (see table 2.6). The t-statistic and p-value of the 
interaction term would be reported to determine a differential impact of 
the 2009 USPSTF depression screening recommendation on the 
diagnosis of depression.  
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Aim #2 Proposed analytical plan 
2.2.1.  Calculate the prevalence (%) of other mental health conditions, 
excluding depression, diagnosed by (1) depression screening status and 
(2) by pre- (2006-2008) and post- (2010-2012) periods. 
 Descriptively observe the patterns using bivariate analyses (i.e., a two-
way tabulation) of these key variables. Design-based F-statistics and p-
value would be reported for each pattern.  
2.2.2.  Conduct a multivariate logistic regression analysis of the mental health 
conditions diagnosed (except depression) on depression screening status, 
time indicator (pre/post), and the interaction of depression screening 
status and time indicator, while controlling for all other socio-
demographic and health-related characteristics (see table 2.6). The t-
statistic and p-value of the interaction term would be reported to 
determine a differential impact of the 2009 USPSTF depression 
screening recommendation on the diagnosis of mental health conditions 
other than depression.  
2.3.1.  Calculate the prevalence (%) of overall antidepressant prescriptions by 
(1) depression screening status and (2) by pre- (2006-2008) and post- 
(2010-2012) periods. 
 Descriptively observe the patterns using bivariate analyses (i.e., a two-
way tabulation) of these key variables. Design-based F-statistics and p-
value would be reported for each pattern.  
2.3.2.  Conduct a multivariate logistic regression analysis of the overall 
antidepressant prescriptions on depression screening status, time 
indicator (pre/post), and the interaction of depression screening status 
and time indicator, while controlling for all other socio-demographic and 
health-related characteristics (see table 2.6). The t-statistic and p-value 
of the interaction term would be reported to determine a differential 
impact of the 2009 USPSTF depression screening recommendation on 
the overall antidepressant prescriptions.  
2.4.1.  Calculate the prevalence (%) of potentially inappropriate antidepressant 
prescriptions by (1) depression screening status and (2) by pre- (2006-
2008) and post- (2010-2012) periods. 
 Descriptively observe the patterns using bivariate analyses (i.e., a two-
way tabulation) of these key variables. Design-based F-statistics and p-
value would be reported for each pattern.  
2.4.2.  Conduct a multivariate logistic regression analysis of the potentially 
inappropriate antidepressant prescriptions on depression screening 
status, time indicator (pre/post), and the interaction of depression 
screening status and time indicator, while controlling for all other socio-
demographic and health-related characteristics (see table 2.6). The t-
statistic and p-value of the interaction term would be reported to 
determine a differential impact of the 2009 USPSTF depression 
screening recommendation on the overall antidepressant prescriptions.  
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Aim #3: Aim #3 focuses on the effect of depression screening on four different 
outcomes—(1) the diagnosis of depression; (2) the diagnosis of mental health conditions 
other than depression; (3) overall antidepressant prescriptions; and (4) potentially 
inappropriate antidepressant prescriptions—in clinical practice. To determine such effect, 
however, selection bias of physicians (e.g., physicians selectively choose whom to give 
depression screening) is a serious methodological concern.26 To address such concern, an 
instrumental variable (IV) analysis is proposed in this aim #3, and at least two 
instrumental variables would be selected: (1) diet/nutrition education and counseling, and 
(2) exercise education and counseling. The rationale for selecting these IVs are explained 
in Mojtabai’s work (i.e., they are likely correlated with depression screening and are not 
likely associated with the outcomes).26 A proposed analytical plan by each specific sub-
aim in aim #3 is described below (see Table 2.7.3). Selected variables for each analytical 
plan are summarized in Table 2.6. 
Table 2.7.3. Proposed analytical plan by specific aim #3 
Aim #3 Proposed analytical plan 
3.1.1.  Check the assumption of instrumental variables (diet/nutrition and 
exercise counseling) are highly correlated with the key independent 
variable, depression screening, and have a low correlation with the key 
dependent variable, diagnosis of depression. 
 When the assumption is met, conduct a two-stage least squares (2SLS) 
multivariate regression analysis: that is, (1) regress depression screening 
on instrumental variables; then, (2) regress diagnosis of depression on 
the stored information from (1), while controlling for all other socio-
demographic and health-related characteristics (see table 2.6).  
 Check the regression model for (1) endogeneity and (2) over-
identification issues using a Hausman specification test, provided as a 
post-estimation technique in Stata.30 
 Report the full model with coefficients, 95% CIs, and p-values to discuss 
the role of depression screening on the diagnosis of depression.      
3.2.1.  Check the assumption of instrumental variables (diet/nutrition and 
exercise counseling) are highly correlated with the key independent 
variable, depression screening, and have a low correlation with the key 
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Aim #3 Proposed analytical plan 
dependent variable, diagnosis of mental health conditions other than 
depression. 
 When the assumption is met, conduct a two-stage least squares (2SLS) 
multivariate regression analysis: that is, (1) regress depression screening 
on instrumental variables; then, (2) regress diagnosis of mental health 
conditions other than depression on the stored information from (1), 
while controlling for all other socio-demographic and health-related 
characteristics (see table 2.6).  
 Check the regression model for (1) endogeneity and (2) over-
identification issues using a Hausman specification test, provided as a 
post-estimation technique in Stata.30 
 Report the full model with coefficients, 95% CIs, and p-values to discuss 
the role of depression screening on the diagnosis of mental health 
conditions other than depression.      
3.3.1.  Check the assumption of instrumental variables (diet/nutrition and 
exercise counseling) are highly correlated with the key independent 
variable, depression screening, and have a low correlation with the key 
dependent variable, overall antidepressant prescriptions. 
 When the assumption is met, conduct a two-stage least squares (2SLS) 
multivariate regression analysis: that is, (1) regress depression screening 
on instrumental variables; then, (2) regress overall antidepressant 
prescriptions on the stored information from (1), while controlling for all 
other socio-demographic and health-related characteristics (see table 
2.6).  
 Check the regression model for (1) endogeneity and (2) over-
identification issues using a Hausman specification test, provided as a 
post-estimation technique in Stata.30 
 Report the full model with coefficients, 95% CIs, and p-values to discuss 
the role of depression screening on the overall antidepressant 
prescriptions.      
3.4.1.  Check the assumption of instrumental variables (diet/nutrition and 
exercise counseling) are highly correlated with the key independent 
variable, depression screening, and have a low correlation with the key 
dependent variable, potentially inappropriate antidepressant 
prescriptions. 
 When the assumption is met, conduct a two-stage least squares (2SLS) 
multivariate regression analysis: that is, (1) regress depression screening 
on instrumental variables; then, (2) regress potentially inappropriate 
antidepressant prescriptions on the stored information from (1), while 
controlling for all other socio-demographic and health-related 
characteristics (see table 2.6).  
 Check the regression model for (1) endogeneity and (2) over-
identification issues using a Hausman specification test, provided as a 
post-estimation technique in Stata.30 
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Aim #3 Proposed analytical plan 
 Report the full model with coefficients, 95% CIs, and p-values to discuss 
the role of depression screening on the potentially inappropriate 
antidepressant prescriptions.      
 
 
In each aim, I would use Stata 13.131 for all statistical analyses and would employ 
the svy commands in Stata to account for the complex sample design (i.e., unequal 
probability of selection, clustering and stratification) as well as pooling multiple year 
datasets from the NAMCS.  
 
2.4. Potential challenges, limitations, and solutions 
The proposed study is not free from potential challenges and limitations. First, the 
NAMCS does not collect injury-related ICD-9-CM diagnostic codes (e.g., EXXX.XX) 
since 2005. For consistency, I did not include one of the conditions when defining the 
potentially inappropriate use of antidepressants—interaction between history of falls or 
fractures (E880-E888) and TCAs/SSRIs (see Table 2.3). It must be clearly 
acknowledged. Second, a number of patient-related omitted variables (e.g., marital status, 
nativity status, income and educational attainment) should be acknowledged, as they can 
potentially confound my results. Fourth, in aim #3, while the selection of instrumental 
variables was grounded on a previous study,26 they may not be ideal or may still have 
some endogeneity problems in my study. In such case, I may need to approach the 
research questions differently—using structural equation modeling, for example. As a 
scientific researcher, I would further acknowledge other potential challenges and 
limitations and try to address them clearly throughout my study.  
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Table 2.2. Antidepressant medications by class4  
Tricyclics (TCAs) Monoamine Oxidase Inhibitors (MAOIs) 
 Amitriptylinea), b), f) 
 
 Isocarboxazid 
 Amoxapineb)  Phenelzine 
 Clomipraminea), b), f)  Tranylcypromine 
 Desipramineb)  Rasagilinec) 
 Doxepina), b), f)  Selegilinec) 
 Imipraminea), b), f) Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 
 Maprotiline  Desvenlafaxine 
 Nortriptylineb)  Duloxetine 
 Protriptylineb)  Levomilnaciprane) 
 Trimipraminea), b), f)  Venlafaxine 
Serotonin Modulators  Milnaciprand) 
 Nefazodone Miscellaneous 
 Trazodone  Bupropion 
 Vilazodonee)  Mirtazapine 
 Vortioxetinee)   
Selective Serotonin Reuptake Inhibitors (SSRIs)   
 Citalopram   
 Escitalopram   
 Fluoxetine   
 Fluvoxamine   
 Paroxetineb)   
  Sertraline     
Note: a) denotes tertiary TCAs; b) denotes drugs with strong anticholinergic properties; c) denotes a MAO-B inhibitor and is primarily classified as anti-Parkinsonian agents; d) is 
primarily classified as fibromyalgia agents; e) indicates that it is not available in NAMCS; and f) indicates that it should be avoided, regardless of diagnosis, according to 2012 
Beers criteria.   
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Table 2.3. 2012 Beers criteria for potentially inappropriate antidepressant use in older adults due to drug-disease or drug-
syndrome interactions that may exacerbate the disease or syndrome12 
Disease or syndrome  
(ICD-9-CM code) 
Antidepressanta) Rationale Recommendation 
Quality 
of 
Evidence 
Strength of 
recommendation 
Cardiovascular           
 Syncope  
(780.2, 992.1) 
Tertiary TCAs 
Increase risk of orthostatic hypotension 
or bradycardia 
Avoid Moderate Strong 
Central nervous system        
 
Chronic seizures or 
epilepsy  
(345, 780.33) 
bupropion;  
maprotiline 
Lowers seizure threshold; may be 
acceptable in patients with well-
controlled seizures in whom alternative 
agents have not been effective 
Avoid Moderate Strong 
 
Delirium  
(290.11, 290.3, 290.41, 
291.0, 292.81, 293.0, 293.1) 
TCAs;  
Anticholinergics 
Induce or worsen delirium in older 
adults; if discontinuing drugs used 
chronically, taper to avoid withdrawal 
symptoms 
Avoid Moderate Strong 
 
Dementia and cognitive 
impairment  
(290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 
331.0, 331.19, 331.82, 
331.83) 
Anticholinergics Avoid because of adverse CNS effects Avoid High Strong 
 
History of falls or fractures 
(E880-E888)b) 
TCAs; SSRIs 
Ability to produce ataxia, impaired 
psychomotor function, syncope, and 
additional falls 
Avoid unless safer 
alternatives are not 
available 
High Strong 
Gastrointestinal        
 
Chronic constipation  
(564) 
Tertiary TCAs; 
Anticholinergics 
Can worsen constipation 
Avoid unless no 
other alternatives 
Moderate 
to low 
Weak 
  
Lower urinary tract 
symptoms, benign 
prostatic hyperplasia  
(600) 
Anticholinergics 
May decrease urinary flow and cause 
urinary retention 
Avoid in men Moderate 
Inhaled agents: 
strong; others: 
weak 
Note: a) refers to appendix 1 for full description; and b) excluded in the analysis for consistency, as NAMCS only collected external cause information using ICD-9-CM in 2002-
2004.  
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Table 2.4. 2002 Beers criteria for potentially inappropriate antidepressant use in 
older adults, based on 2012 Beers criteria.12,13 
Medications moved to another category or modified since 2002 
Independent 
of diagnoses 
or conditions 
 None 
Considering 
diagnoses 
 Fluoxetine, citalopram, fluvoxamine, paroxetine, and sertraline 
with syndrome of inappropriate antidiuretic hormone secretion 
Medications removed since 2002  
Independent 
of diagnoses 
or conditions 
 Daily fluoxetine 
 
Considering 
diagnoses 
 Fluoxetine with anorexia and malnutrition 
 Monoamine oxidase inhibitors (MAOIs) with insomnia 
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Table 2.5. Mental health diagnosis14 
Diagnosis 
ICD-9-CM diagnostic code  
(290-319) 
Affective disorder   
 Major depression 296.2 & 296.3 
 Dysthymia 300.4 
 
Other affective disorder 
296.1, 296.81, 296.82, 296.9, 
& 311.0 
Bipolar disorder   
 
Bipolar disorder 
296.00-296.06, 296.40-
296.46, 296.50-296.56, 
296.60-296.66, 296.7, 
296.80, 296.89 
Schizophrenia   
 Schizophrenia 295 
Delirium, dementia, and other cognitive impairment   
 Delirium 
290.11, 290.3, 290.41, 291.0, 
292.81, 293.0, 293.1 
 
Dementia and other cognitive impairment 
290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 
331.0, 331.19, 331.82, 
331.83 
Anxiety Disorders   
 Generalized anxiety disorder (GAD) 300.02 
 Panic disorder with or without agoraphobia 300.01 & 300.21 
 Obsessive-compulsive disorder 300.3 
Personality Disorders   
 Personality disorders 301 
Others Otherwise 
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Table 2.6. Key variables by specific aim. 
Variable Operationalization 
Specific aim 
Aim #1 Aim #2 Aim #3 
1
.1
.1
. 
1
.1
.2
. 
1
.1
.3
. 
1
.2
.1
. 
1
.2
.2
. 
1
.2
.3
. 
2
.1
.1
. 
2
.1
.2
. 
2
.2
.1
. 
2
.2
.2
. 
2
.3
.1
. 
2
.3
.2
. 
2
.4
.1
. 
2
.4
.2
. 
3
.1
.1
. 
3
.2
.1
. 
3
.3
.1
. 
3
.4
.1
. 
Year                       
 2002-2004   X X X X X X              
 2005   X X X X X X              
 2006-2008   X X X X X X X X X X X X X X      
 2009   X X X X X X              
 2010-2012   X X X X X X X X X X X X X X X X X X 
Antidepressant use                       
 Overall antidepressant 
prescriptions 
1=yes; 0=no 
D
V 
D
V 
D
V 
        
D
V 
D
V 
     
D 
V 
 
 
Potentially inappropriate 
antidepressant 
prescriptions (2002 
version) 
1=yes; 0=no    
D
V 
D
V 
D
V 
      D
V 
D
V 
    
D 
V 
 
Potentially inappropriate 
antidepressant 
prescriptions (2012 
version) 
1=yes; 0=no    
D
V 
D
V 
D
V 
      D
V 
D
V 
    
D 
V 
 
Potentially inappropriate 
antidepressant 
prescriptions (2002 
version for 2002-2011 and 
2012 version for 2012) 
1=yes; 0=no    
D
V 
D
V 
D
V 
      D
V 
D
V 
    
D 
V 
Mental health conditions                       
 Mental health 
1=major depression; 
2=dysthymia; 3=other 
affective disorders; 4=bipolar 
disorders; 5=schizophrenia; 
6=delirium, dementia and 
other cognitive deficits; 
7=anxiety-related disorders; 
 C C  C C              
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8=personality disorders; 
9=others 
 Depression 
1=major depression; 
0=otherwise 
       
D
V 
D
V 
      D 
V 
   
 Mental health conditions 
other than depression 
1= 2 to 9 in mental health; 
0=otherwise 
         
D
V 
D
V 
      
D 
V 
  
Screening/counseling                       
 Depression screening 1=yes; 0=no        IV IV IV IV IV IV IV IV IV IV IV IV 
 Diet/nutrition education 
and counseling 
1=yes; 0=no                 
Inst
V 
Inst
V 
Inst
V 
Inst
V 
 Exercise education and 
counseling 
1=yes; 0=no                 
Inst
V 
Inst
V 
Inst
V 
Inst
V 
Socio-demographic 
characteristics 
                      
 Age 1=65-74; 2=75-84; 3=85+  C C  C C  C  C  C  C C C C C 
 Gender 1=male; 2=female  C C  C C  C  C  C  C C C C C 
 Race/ethnicity 
1=non-Hispanic white; 
2=non-Hispanic black; 
3=Hispanic; 4=others 
 C C  C C  C  C  C  C C C C C 
 Region 
1=Northeast; 2=Midwest; 
3=South; 4=West 
 C C  C C  C  C  C  C C C C C 
 Primary source of 
payment 
1=private; 2=Medicare; 
3=Medicaid; 4=others 
 C C  C C  C  C  C  C C C C C 
Health-related, clinical 
characteristics 
                      
 Reason for visit 
1=acute problem; 2=routine 
chronic problem; 3=pre-/post-
surgery; 4=preventive care 
 C C  C C  C  C  C  C C C C C 
 Repeat of visits in the past 
12 months 
0=none; 1=1-2 visits; 2=3-5 
visits; 3=6+ visits 
 C C  C C  C  C  C  C C C C C 
 Physician specialty 
1=primary care; 
2=psychiatry; 3=others 
 C C  C C  C  C  C  C C C C C 
 Type of medical practice 
1=solo/group practice; 
2=others 
 C C  C C  C  C  C  C C C C C 
 Metropolitan statistical 
area (MSA) 
1=yes; 0=no  C C  C C  C  C  C  C C C C C 
 Provision of 
psychotherapy 
1=yes; 0=no  C C  C C  C  C  C  C C C C C 
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 Time spent with doctor 
1= < 15 min.; 2=15-20 min; 
3=21-30 min; 4= > 30 min. 
 C C  C C  C  C  C  C C C C C 
 Multiple chronic 
conditions 
0=none; 1=1; 2=2-3; 4=4+  C C  C C  C  C  C  C C C C C 
  Number of medications 1=0-2; 2=3-5; 3=6+   C C   C C   C   C   C   C C C C C 
Note: X=included; DV=dependent variable; IV=independent variable; InstV=instrumental variable; and C=covariate. 
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ABSTRACT 
 Using data from the 2002-2012 National Ambulatory Medical Care Survey, we 
calculated that the prevalence of overall antidepressant prescriptions increased almost 
twofold from 5.2% in 2002 to 10.1% in 2012 among older adults in their office-based 
visits. Approximately one in 10 antidepressant-related visits (or 2.2 million visits 
annually) among older adults was exposed to the risk of potentially avoidable adverse 
drug events. Amitriptyline and doxepin were the two most frequent disease-independent 
potentially inappropriate antidepressants. Racial/ethnic minorities, and Medicaid 
beneficiaries were associated with higher odds of potentially inappropriate antidepressant 
prescriptions (p<0.05). Efforts to minimize potentially inappropriate antidepressant 
prescriptions are needed. 
 
Word Count: 98 (out of 100) 
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3.1 Introduction 
Antidepressant use increased nearly 400% between periods of 1988-1994 and 
2005-2008 in all ages,1 and antidepressants are now among the top three most prescribed 
medication classes in the U.S.,2,3 accounting for more than 260 million prescriptions each 
year.3 In addition, antidepressants were the ninth most costly medications during the 
period of 2007-2011 in the U.S., accounting for approximately $20 billion in sales in 
2011.4 Despite the increasing rate of antidepressant use in the general population lately, 
relatively little is known about the prevalence of and possible factors for potentially 
inappropriate use of antidepressants among adults ages 65 and older (hereafter referred to 
as older adults) in office-based outpatient settings.  
Potentially inappropriate medications are not only continuously prescribed,5-8 but 
also remain problematic as they are associated with potentially avoidable healthcare 
expenditures,9-11 estimated to be $7.2 billion in a 2001-2002 study.11 In particular, 
potentially inappropriate medications are associated with increased hospitalization,12-16 
morbidity,17 and mortality rates15 in older adults. Other studies, however, suggest mixed 
results (e.g., no association between potentially inappropriate antidepressant use and 
mortality).18-21 Because avoiding, or reducing, potentially inappropriate use of any 
medication is an effective strategy to minimize adverse drug events and other medication 
errors,5,6,22 the incidence and/or prevalence of potentially inappropriate medication use 
may be used as one of quality of care indicators. 
For quality assurance and performance improvement in office-based outpatient 
settings, the estimates of overall and potentially inappropriate antidepressant use need to 
be updated regularly because the availability and indications of antidepressants continue 
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to evolve. Previous studies have several limitations. For example, previous studies3,23,24 
focused on the individual level rather than at the level of office-based outpatient visit; 
while they are informative understanding individual factors, they rarely convey 
information about physician- and/or practice-related factors. Other studies systematically 
excluded the older adult population,25 were conducted outside the U.S.,26 or are simply 
outdated as they used earlier versions of Beers Criteria reflecting earlier time periods.26,27  
 To fill in existing gaps in literature, we address the following research questions: 
What are the national prevalence rates of overall and potentially inappropriate 
antidepressant prescriptions among older adults in office-based outpatient visits? Which 
potentially inappropriate antidepressants are most commonly prescribed? Which 
demographic and clinical characteristics are associated with the odds of two outcomes, 
overall and potentially inappropriate antidepressant prescriptions, among older adults in 
office-based outpatient visits? In light of updated 2012/2015 Beers Criteria5,6 and rapid 
population aging, we provide an updated descriptive study of U.S. trends for overall and 
potentially inappropriate antidepressant prescriptions among older adults in their office-
based outpatient visits, which may be used as a benchmark for future changes in office-
based outpatient care. 
 
3.2 Methods 
Data Source and Study Sample 
 We used 2002- 2012 National Ambulatory Medical Care Survey (NAMCS), 
administrated by National Center for Health Statistics (NCHS) of the Centers for Disease 
Control and Prevention (CDC).28 The NAMCS is an annual, cross-sectional survey of 
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visits to office-based physicians in outpatient settings. The NAMCS represents office-
based outpatient care and provides reliable information about the provision and/or use of 
ambulatory medical care services in the United States.28 To estimate the prevalence of 
overall and potentially inappropriate antidepressant prescriptions, we selected visits for 
adults ages 65 and over (n=98,719 unweighted) in our analytic sample. For consistency 
of variables across years and sample size issues, we only used the samples from 2009-
2012 (n=46,790 unweighted) for descriptive and multivariate logistic regression analyses. 
We excluded observations with all missing covariates (6.9%), leaving the final sample 
size of 43,550. Using publicly available data, the research procedure for this study was 
exempted from the University of Minnesota Institutional Review Board. Further details 
of the survey, including descriptions, questionnaires, sampling methodology and datasets, 
are publicly available on the NAMCS website.29  
 
Measures 
Dependent variables. The NAMCS collects up to eight medications in 2002-2011 
and up to 10 medications in 2012. Using the 2015 American Hospital Formulary Service 
(AHFS) Compendium,30 Wolters Kluwer’s Drug Facts and Comparisons,31 and previous 
studies,23,26,27,32-34 we identified prescribed antidepressant medications using generic 
names (see Appendix 3.1). We constructed a binary variable (yes/no) for overall 
antidepressant prescriptions.  
Beers and his colleagues developed an inventory of potentially inappropriate 
medications (hereafter referred to as Beers Criteria) for older adults living in nursing 
homes in 1991.35 The Beers Criteria were updated over time5,6,36,37 and are now 
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applicable to older adults in all settings of geriatric care.5,6 For potentially inappropriate 
antidepressant prescriptions, we constructed a binary variable (yes/no) using the 
2012/2015 Beers Criteria (see Appendices 3.1 and 3.2)5 among those who had 
antidepressant-related office-based outpatient visits.  
 
Control variables. Based on previous studies,23,27,33,38-46 we identified a number of 
covariates. We included demographic variables: age (65-74, 75-84, or 85+), gender, 
race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, or others), region 
(Northeast, Midwest, South, or West), primary source of payment (Medicare, Medicaid, 
private, or others), reason for visit (acute problem, routine chronic problem, preventive 
care, or pre- or post-surgery care), and repeat of visits within the past 12 months (none, 1-
2, 3-5, or 6+). We also included clinical characteristics as follow: physician specialty 
(primary care, psychiatry, or others), type of medical practice (solo or others), 
metropolitan statistical area (MSA) status (yes/no), mental health diagnoses (see 
Appendix 3.3),47 psychotherapy provided (yes/no), time spent with doctor (<15, 15-20, 
21-30, or >30 min.), number of chronic conditions (none, 1, 2-3, or 4+), and number of 
medications (0-2, 3-5, or 6+). The number of chronic conditions was based on 14 chronic 
conditions (yes/no) collected by the NAMCS (e.g., arthritis, congestive heart failure, and 
diabetes). The variable, repeat of visits, had the largest missing proportion (28.1%), and 
was imputed based on age, gender and the number of medications using the hotdeck 
imputation technique.48 Other variables that had missing values included: primary source 
of payment (3.8%), reason for visit (1.4%), and the number of chronic conditions (2.3%). 
Observations with all of these missing values (6.9%) were systematically excluded.   
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Data Analysis  
First, we examined the extent to which demographic and clinical characteristics 
differed in older adults by the antidepressant prescription status. We used cross-
tabulations and design-based F-tests to investigate differences by the antidepressant 
prescription status. Second, we estimated prevalence rates of overall and potentially 
inappropriate antidepressant prescriptions by year. Then, we estimated the prevalence of 
potentially inappropriate antidepressant prescriptions by disease (or condition) status. 
Third, we ran multivariate logistic regression analyses to identify demographic and 
clinical factors associated with overall and potentially inappropriate antidepressant 
prescriptions, respectively. We included the year variable to adjust for fixed effects in the 
multivariate logistic regression models in order to correctly estimate the average odds of 
antidepressant prescriptions over the whole time period. We used Stata 13.149 for all 
analyses and we employed the svy commands in Stata to account for the complex sample 
design of the NAMCS (i.e., unequal probability of selection, clustering and stratification). 
 
3.3 Results 
Sample Characteristics 
 Table 3.1 presents demographic and clinical characteristics of visits among older 
adults by the antidepressant prescription status. Except age and region, all characteristics 
had statistically significant differences by the antidepressant prescription status. Older 
adults who made office-based outpatient visits were more likely to be ages under 75 
(50.7%), female (56.8%), predominantly non-Hispanic White (80.7%), and had Medicare 
(81.1%) as a primary source of payment. In antidepressant-related office-based outpatient 
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visits, female older adults and older adults living in the South were more likely to have 
antidepressant prescriptions.  
Furthermore, more than half of older adults had at least three office-based 
outpatient visits (57.6%), and their primary reason for visit was routine chronic problems 
(54.3%). Only 1.1% of all visits made by older adults had psychiatry as a primary 
physician specialty, and the majority of visits was solo (92.3%) as type of medical 
practice, and located in the MSA (87.3%). In addition, majority of older adults was not 
diagnosed with mental health disorders (94.7%) and did not receive psychotherapy 
(99.3%) at the time of data were collected. Finally, more than half of older adults saw 
their doctor less than or equal to 20 minutes (66.5%), had at least two multiple chronic 
conditions (60.2%), and had at least three medications prescribed (54.9%).  
<Table 3.1 about here> 
Prevalence of Antidepressant Prescriptions 
 Figure 3.1 presents the prevalence of overall and potentially inappropriate 
antidepressant prescriptions among older adults in office-based outpatient visits by year. 
The prevalence of overall antidepressant prescriptions increased almost twofold over time 
from 5.2% in 2002 to 10.1% in 2012 (see Appendix 3.4 for exact estimates). The 
prevalence of potentially inappropriate antidepressant prescriptions in given all office-
based outpatient visits made by older adults, however, remains consistent around 1.0% 
across years (see Appendix 3.4 for exact estimates). In given antidepressant-related visits, 
the prevalence of potentially inappropriate antidepressant prescriptions decreases from 
17.0% in 2002 to 10.1% in 2012 (see Figure 3.2).   
<Figures 3.1 and 3.2 about here> 
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Potentially Inappropriate Antidepressant Prescriptions 
 Table 3.2 shows the prevalence of potentially inappropriate antidepressant 
prescriptions by disease (or condition) status in antidepressant-related visits from 2010 to 
2012. Approximately 10.6% of visits with antidepressant prescriptions were identified to 
be potentially inappropriate. Of these visits, 97.2% were disease-independent (i.e., 
regardless of diseases or conditions) potentially inappropriate antidepressants, and 8.2% 
were disease-dependent (i.e., due to drug-disease or drug-syndrome interactions) 
potentially inappropriate antidepressants (mutually not exclusive). About 5.0% of visits 
with potentially inappropriate antidepressant prescriptions were both disease-independent 
and disease-dependent. Among disease-independent potentially inappropriate 
antidepressants, the most common antidepressants were amitriptyline (67.7%), doxepin 
(15.4%), imipramine (8.3%), and clomipramine (5.9%). For disease-dependent 
potentially inappropriate antidepressants, chronic constipation and tertiary tricyclics or 
anticholinergics (7.0%), and benign prostatic hyperplasia and anticholinergics (1.1%) 
were the two most common cases.   
<Table 3.2 about here> 
Odds of Antidepressant Prescriptions 
 Table 3.3 presents the results of two multivariate logistic regression models 
estimating the odds of two outcomes: overall and potentially inappropriate antidepressant 
prescriptions. When adjusted for other covariates, being ages 75-84 and 85+ had 
significantly lower odds of overall antidepressant prescriptions by 14.7% and 25.3% 
(P<0.05), respectively. When compared to non-Hispanic Whites, non-Hispanic Blacks, 
Hispanics and others had significantly lower odds of overall antidepressant prescriptions 
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by 56.0%, 23.4% and 53.2% (P<0.05), respectively. Older adults who made visits to 
psychiatry had 10.71 times higher odds of overall antidepressant prescriptions when 
compared to those with primary care visits (95% CI 5.67-20.21; P<0.001). When 
compared to those who were not diagnosed with any mental disorder, older adults with 
mental health diagnoses had 5.78 times higher odds of overall antidepressant 
prescriptions (95% CI 4.61-7.23; P<0.01). Compared to those with no medication 
prescribed, older adults with three to five medications had 8.03 times higher odds of 
overall antidepressant prescriptions (95% CI 6.29-10.25; P<0.001) and those with equal 
to or more than six medications had 23.35 times higher odds of overall antidepressant 
prescriptions (95% CI 18.87-28.90; P<0.001).  
 For potentially inappropriate antidepressant prescriptions as a key outcome of 
interest, racial/ethnic minority groups other than non-Hispanic Blacks and Hispanics 
were 3.61 times higher odds when compared to non-Hispanic Whites (95% CI 1.49-8.72; 
P<0.001). When compared to older adults with Medicare as a primary source of payment, 
those with Medicaid as a primary source of payment had 2.54 times higher odds of 
potentially inappropriate antidepressant prescriptions (95% CI 1.04-6.18; P<0.05). Older 
adults with six or more repeated visits had significantly lower odds of potentially 
inappropriate antidepressant prescriptions by 46% (P<0.05). While older adults, who had 
psychiatry as their primary visits, had 3.97 times the odds of potentially inappropriate 
antidepressant prescriptions (95% CI 1.53-10.33; P<0.05),  older adults with mental 
health diagnoses had lower odds of potentially inappropriate antidepressant prescriptions 
by 83.1% (P<0.001). Unlike the case in the overall antidepressant prescriptions, the time 
trend was associated with the odds of potentially inappropriate antidepressant 
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prescriptions. For instance, when compared to the year 2009, subsequent following years 
were almost twice higher odds of potentially inappropriate antidepressant prescriptions 
(P<0.05), when controlling for other covariates.   
<Table 3.3 about here> 
 
3.4 Discussion 
This is the first study to use nationally representative data for estimating the 
prevalence rates of overall and potentially inappropriate antidepressant prescriptions, and 
factors associated with these outcomes among older adults in their office-based outpatient 
visits using the 2012/2015 Beers Criteria. First, one of major findings was that the overall 
antidepressant prescriptions in given all office-based outpatient visits made by older 
adults increased nearly twofold from 5.2% in 2002 to 10.1% in 2012. This is similar to 
previous studies conducted in different settings in the U.S.50-52 Descriptively speaking, 
the finding suggests that the majority of antidepressant prescriptions was provided 
without psychiatric diagnoses or by non-psychiatrist providers, and this is consistent with 
a previous study.52 Estimates in this study, however, are a bit higher as the older adult 
population was the primary population of interest rather than the general public.52 In 
another study conducted by Mojtabai and Olfson,3 they found that the long-term use of 
antidepressants may explain the recent increase of the overall antidepressant prescriptions 
in adults ages 18 and over. Future research is needed if the increasing rate of overall 
antidepressant prescriptions coincides with older adults’ long-term use of antidepressants 
in office-based outpatient settings. 
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Second, the prevalence of potentially inappropriate antidepressant prescriptions 
among older adults in given all office-based outpatient visits remains stable around 1.0% 
across years. However, approximately one in 10 older adults with antidepressant-related 
visits is exposed to the potentially inappropriate antidepressant use. In other words, at 
least 2.2 million office-based outpatient visits made by older adults each year, on average, 
are at the risk of developing potentially avoidable drug-related adverse events. Some 
patterns were found in this prevalence. For instance, amitriptyline and doxepin were the 
two most frequent disease-independent antidepressants prescribed, accounting for more 
than 70% of the potentially inappropriate antidepressant prescriptions. This finding is 
supported by previous studies that these antidepressant agents are one of the most 
common causes for potentially inappropriate medication use in older adults.27,53,54 Such a 
finding warrants that we should improve healthcare providers’ prescribing practices to 
reduce potentially inappropriate antidepressant prescriptions. For example, education 
may help healthcare providers better understand that disease-independent and disease-
dependent potentially inappropriate antidepressants should be avoided, even though the 
Beers Criteria and other guidelines do not always serve as a substitute for their judgment 
when prescribing. An alternative, possible explanation for this phenomenon is that 
healthcare providers do not feel the need to stop prescribing these medications as they 
work well for older patients that they see. Thus, future research is needed to qualitatively 
better understand the prescribing patterns of these medications among older patients.    
Factors associated with the increased likelihood of visits involving overall 
antidepressant prescriptions among older adults included being female, seeing 
psychiatrists, and having mental health diagnoses and number of medications. The 
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finding posits a question whether or not female older adults are more receptive about 
antidepressants as a treatment option than their counterparts. In the case of the number of 
medications, it seems plausible as a previous study showed that antidepressants are one of 
the most common medications in older adults’ polypharmacy.46 Being ages 75 or older 
and racial/ethnic minorities were associated with the decreased likelihood of visits 
involving overall antidepressant prescriptions. As previous studies found,55,56 
racial/ethnic minorities may be under-treated with antidepressants among older adults.   
Factors associated with the increased likelihood of visits involving potentially 
inappropriate antidepressant prescriptions among older adults who had antidepressant-
related visits were: racial/ethnic minorities other than non-Hispanic Blacks and Hispanics, 
Medicaid as a primary source of payment, seeing psychiatrists, and the non-MSA status. 
In the case of racial/ethnic minorities and Medicaid beneficiaries, it appears that because 
they often have poor access to quality care and have lower quality of care for mental 
health conditions in general, they may also be exposed to a greater likelihood of 
potentially inappropriate antidepressant prescriptions. Future research is needed to 
address this issue. Surprisingly, the finding leaves a question about the relationship 
between seeing psychiatrists and potentially inappropriate antidepressant prescriptions. 
One possible explanation is that primary care providers may be more likely to adhere the 
guidelines related to potentially inappropriate antidepressant use than psychiatrists. 
Future research is needed to better understand the role of seeing psychiatrists versus 
primary care providers on the potentially inappropriate antidepressant prescriptions. With 
regards to the MSA status, future research is also needed if MSA-level geographic 
disparity exists in prescribing patterns of potentially inappropriate antidepressants across 
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the country. Finally, having more than five visits within the past 12 months and mental 
health diagnoses were associated with the decreased likelihood of such visits. It seems 
that those with frequent visits and mental health diagnoses may have received appropriate 
care, including appropriate antidepressant use. 
This study is not without limitations. First, the NAMCS data capture up to three 
diagnoses in a sampled visit, and the survey response rate has declined in the last few 
years due to a redesign of sampling strategy. Such factors may cause underreporting 
potentially inappropriate antidepressant prescriptions due to drug-disease or drug-
syndrome interactions. Second, when referrals are made across different healthcare 
providers, patient information is often lost.57 Furthermore, healthcare providers may have 
refilled antidepressant prescriptions without coding the mental health diagnoses at each 
visit. This may also have led to underreporting of mental health diagnoses and potentially 
inappropriate antidepressant prescriptions. Third, there are potential confounders in 
multivariate logistic regression models. For example, socio-economic and other variables 
(e.g., education and marital status) are not collected. Interpretations of findings should 
consider these limitations. 
Overall, our study highlights that the prevalence of overall antidepressant 
prescriptions in older adults continues to increase up to 10.1% in office-based outpatient 
visits, and the potentially inappropriate antidepressant prescriptions remain a persistent 
problem. Efforts to minimize potentially inappropriate antidepressant prescriptions may 
still be needed by providing educational interventions to healthcare providers, targeting 
specific antidepressant agents (e.g., amitriptyline and doxepin). To further guide policy 
changes, future research is also needed to evaluate factors that cause potentially 
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inappropriate antidepressant prescriptions in clinical practice. The on-going research will 
improve value-based quality of care among older adults who are prescribed 
antidepressants in office-based outpatient settings. 
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Figure 3.1. National trends of antidepressant prescriptions among older adults in 
office-based outpatient settings, 2002-2012 NAMCS. 
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Figure 3.2. National trend of potentially inappropriate antidepressant prescriptions 
in given antidepressant-related visits, 2002-2012 NAMCS. 
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Table 3.1. Selected characteristics (weighted percent) of older adults in office-based 
outpatient settings by prescription status of antidepressant, 2009-2012 NAMCS. 
  
Antidepressant prescribed 
Without 
antidepressants 
Total P-value‡ 
    
Potentially 
inappropriate 
Appropriate 
Age  
    
 
 
65-74 57.2 50.0 50.7 50.7 
0.4836 
 
75-84 32.3 36.3 36.0 36.0 
 
85+ 10.5 13.8 13.3 13.3 
Gender 
    
 
 
Female 69.4 67.7 55.6 56.8 
<0.0001 
 
Male 30.6 32.4 44.4 43.2 
Race/ethnicity 
    
 
 
Non-Hispanic White 81.0 86.6 80.1 80.7 
<0.0001 
 
Non-Hispanic Black 4.4 4.1 7.8 7.4 
 
Hispanic 8.2 7.4 7.7 7.7 
 
Othersa) 6.4 1.9 4.4 4.2 
Region 
    
 
 
Northeast 17.6 16.3 18.2 18.0 
0.7941 
 
Midwest 22.3 21.3 20.4 20.5 
 
South 40.9 38.8 38.4 38.5 
 
West 19.2 23.6 23.0 23.0 
Source of payment  
    
  Medicare  80.0 81.1 81.2 81.1 
0.0149 
 
 
Medicaid 3.7 1.7 1.4 1.5 
Private 13.7 14.6 15.7 15.6 
 
Othersb) 2.6 2.6 1.8 1.9 
Reason for visit 
    
 
 
Acute problem 26.4 23.7 25.9 25.7 
0.0002 
 
Routine chronic 
problem 
54.0 59.8 53.7 54.3 
 
Preventive care 9.0 11.0 11.8 11.7 
 
Pre- or post-surgery 10.6 5.5 8.5 8.3 
Repeat of visits 
    
 
 
0 visit 6.5 5.9 7.8 7.6 
<0.0001 
 
1-2 visits 32.4 28.5 35.4 34.7 
 
3-5 visits 36.4 33.2 32.9 32.9 
 
6+ visits 24.7 32.3 24.0 24.7 
Physician specialty 
    
 
 
Primary care 50.8 50.2 38.9 40.1 
<0.0001 
 
Psychiatry 5.2 7.3 0.5 1.1 
 
Other specialtiesc) 44.1 42.5 60.6 58.8 
Type of medical 
practice     
 
 
Solo 91.6 89.6 92.6 92.3 
0.0023 
 
Othersd) 8.4 10.4 7.4 7.7 
MSA status 
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MSA 79.9 86.0 87.5 87.3 
0.0471 
 
Non-MSA 20.1 14.0 12.5 12.7 
Mental health 
diagnosise)     
 
 
None / missing 91.6 76.1 96.6 94.7 
<0.0001 
 
Major depression 2.0 3.4 0.1 0.5 
 
Dysthymia 1.2 1.8 0.1 0.3 
 
Other affective 
disorders 
1.2 7.6 0.5 1.1 
 
Bipolar disorders 0.4 0.8 0.1 0.2 
 
Schizophrenia 0.6 0.4 0.1 0.1 
 
Delirium, dementia, 
and other cognitive 
deficits 
0.2 2.5 0.7 0.8 
 
Anxiety-related 
disorders 
0.9 1.5 0.1 0.2 
 
Personality 
disorders 
0.0 0.2 0.0 0.0 
 
Others 1.9 5.8 1.7 2.1 
Psychotherapy 
provided      
 
 
Yes 2.4 4.7 0.3 0.7 
<0.0001 
 
No 97.6 95.3 99.7 99.3 
Time spent with doctor 
    
 
 
< 15 min. 17.8 15.0 19.9 19.5 
0.0013 
 
15-20 min. 46.0 47.1 47.0 47.0 
 
21-30 min. 22.2 25.2 21.0 21.4 
 
> 30 min. 14.0 12.7 12.0 12.1 
Multiple chronic 
conditions (MCCs)      
 
None 7.4 7.5 16.4 15.5 
<0.0001 
 
1 24.1 19.7 24.8 24.4 
 
2-3 45.6 44.6 41.9 42.2 
 
4+ 22.9 28.2 16.9 18.0 
Number of medications 
    
 
 
0 0.0 0.0 23.7 21.3 
<0.0001 
 
1-2 4.6 8.2 25.5 23.8 
 
3-5 23.5 20.3 21.4 21.3 
 6+ 71.9 71.5 29.4 33.6 
Sample size 
    
 
 
Unweighted sample 466 3,926 39,158 43,550 
   Weighted population 2,259,397 22,189,574 220,872,034 245,321,006   
Note: ‡ Comparison across three groups. a) includes Asians, American Indian/Alaska Natives (AIANs), Native 
Hawaiian or Other Pacific Islanders (NHOPI), and multiple races; b) includes worker’s compensation, self-pay, no 
charge, and others; c) includes general surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, 
dermatology, urology, neurology, ophthalmology, otolaryngology, and others; d) includes federally qualified health 
center (FQHC), non-federal government clinic, family planning clinic, health maintenance organization (HMO) or 
other prepaid practice plan, and faculty practice plan; and e) refers to appendix 3.3. 
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Table 3.2. Prevalence of potentially inappropriate antidepressant prescriptions 
among older adults with antidepressant prescriptions in office-based outpatient 
visits, 2010-2012 NAMCS. 
 
Potentially inappropriate antidepressant 
prescription 
 No (n=3926) Yes (n=466) 
Regardless of diseases or conditions 0.0% 97.2% 
   Amitriptyline 0.0% 67.7% 
   Clomipramine 0.0% 5.9% 
   Doxepin 0.0% 15.4% 
   Imipramine  0.0% 8.3% 
   Trimipramine 0.0% 0.0% 
Due to drug-disease or drug-syndrome 
interactions 
0.0% 8.2% 
   Syncope x tertiary TCAs* 0.0% 0.1% 
   Seizure x bupropion or maprotiline 0.0% 0.0% 
   Delirium x anticholinergics 0.0% 0.0% 
   Dementia and cognitive impairment x            
       anticholinergics 
0.0% 0.0% 
   Constipation x tertiary TCAs or  
       anticholinergics 
0.0% 7.0% 
   Prostatic hyperplasia x anticholinergics 0.0% 1.1% 
Note: *TCAs indicate tricyclics. 
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Table 3.3. Adjusted odds ratios (AOR) for prescribing antidepressants among older 
adults in office-based outpatient settings, NAMCS 2009-2012. 
  
Potentially inappropriate 
prescription of antidepressants† 
  
Overall prescription of 
antidepressants¶ 
    AOR 95% CI   AOR 95% CI 
Age  
     
 
65-74 1.00 
  
1.00 
 
 
75-84 0.84 0.60 - 1.18 
 
0.85* 0.75 - 0.97 
 
85+ 0.76 0.45 - 1.28 
 
0.75** 0.61 - 0.91 
Gender 
     
 
Male 1.00 
  
1.00 
 
 
Female 1.14 0.84 - 1.57 
 
1.60*** 1.43 - 1.78 
Race/ethnicity 
     
 
Non-Hispanic White 1.00 
  
1.00 
 
 
Non-Hispanic Black 1.17 0.58 - 2.35 
 
0.44*** 0.34 - 0.57 
 
Hispanic 1.21 0.68 - 2.15 
 
0.77* 0.61 - 0.96 
 
Othersa) 3.61** 1.49 - 8.72 
 
0.47** 0.28 - 0.77 
Region 
     
 
Northeast 1.00 
  
1.00 
 
 
Midwest 1.01 0.63 - 1.63 
 
0.97 0.80 - 1.18 
 
South 1.04 0.68 - 1.59 
 
1.16 0.97 - 1.40 
 
West 0.82 0.54 - 1.25 
 
1.16 0.93 - 1.45 
Source of payment  
     
 
Medicare  1.00 
  
1.00 
 
 
Medicaid 2.54* 1.04 - 6.18 
 
1.33 0.96 - 1.86 
 
Private 1.02 0.70 - 1.50 
 
1.04 0.87 - 1.24 
 
Othersb) 1.25 0.61 - 2.55 
 
1.12 0.81 - 1.55 
Reason for visit 
     
 
Acute problem 1.00 
  
1.00 
 
 
Routine chronic 
problem 
0.89 0.63 - 1.28 
 
0.97 0.85 - 1.11 
 
Pre- or post-surgery 1.54 0.79 - 2.99 
 
1.10 0.87 - 1.40 
 
Preventive care 0.65 0.40 - 1.06 
 
0.91 0.78 - 1.06 
Repeat of visits 
     
 
0 visit 1.00 
  
1.00 
 
 
1-2 visits 0.75 0.42 - 1.34 
 
0.93 0.74 - 1.15 
 
3-5 visits 0.76 0.44 - 1.33 
 
0.94 0.71 - 1.24 
 
6+ visits 0.54* 0.31 - 0.95 
 
1.09 0.85 - 1.41 
Physician specialty 
     
 
Primary care 1.00 
  
1.00 
 
 
Psychiatry 3.97** 1.53 - 10.33 
 
10.71*** 5.67 - 20.21 
 
Other specialtiesc) 0.81 0.57 - 1.16 
 
0.90 0.79 - 1.03 
Type of medical practice 
     
 
Solo 1.00 
  
1.00 
 
 
Othersd) 0.73 0.47 - 1.14 
 
1.17 0.96 - 1.43 
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MSA status 
     
 
MSA 1.00 
  
1.00 
 
 
Non-MSA 1.93** 1.19 - 3.13 
 
0.94 0.74 - 1.18 
Mental health diagnosise) 
     
 
No / missing 1.00 
  
1.00 
 
 
Yes 0.17*** 0.09 - 0.32 
 
5.78*** 4.61 - 7.23 
Psychotherapy provided  
     
 
No 1.00 
  
1.00 
 
 
Yes 0.55 0.22 - 1.36 
 
1.58 0.94 - 2.66 
Time spent with doctor 
     
 
< 15 min. 1.00 
  
1.00 
 
 
15-20 min. 0.90 0.60 - 1.37 
 
1.10 0.94 - 1.29 
 
21-30 min. 0.82 0.50 - 1.35 
 
1.10 0.92 - 1.32 
 
> 30 min. 0.98 0.58 - 1.67 
 
0.95 0.75 - 1.19 
Multiple chronic 
conditions (MCCs)      
 
None 1.00 
  
1.00 
 
 
1 1.42 0.81 - 2.49 
 
1.07 0.85 - 1.35 
 
2-3 1.18 0.69 - 2.00 
 
1.07 0.85 - 1.35 
 
4+ 0.87 0.53 - 1.41 
 
1.24 0.95 - 1.63 
Number of medications 
     
 
0-2 1.00 
  
1.00 
 
 
3-5 1.66 0.95 - 2.92 
 
8.03*** 6.29 - 10.25 
 
6+ 1.36 0.72 - 2.56 
 
23.35*** 18.87 - 28.90 
Survey year 
     
 
2009 1.00 
  
1.00 
 
 
2010 1.85* 1.11 - 3.08 
 
1.04 0.89 - 1.22 
 
2011 2.16** 1.32 - 3.53 
 
1.01 0.85 - 1.20 
 2012 1.92** 1.26 - 2.93   1.15 0.98 - 1.34 
Sample size 
     
 
Unweighted sample 4,392 
 
43,550 
  Weighted population 24,448,971   245,321,006 
F-statistic 4.33***   76.65*** 
Note: † the denominator is antidepressant-related visits, and ¶ the denominator is all visits. * <0.05; **<0.01; 
***<0.001. a) includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders 
(NHOPI), and multiple races; b) includes worker’s compensation, self-pay, no charge, and others; c) includes general 
surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, neurology, 
ophthalmology, otolaryngology, and others; d) includes federally qualified health center (FQHC), non-federal 
government clinic, family planning clinic, health maintenance organization (HMO) or other prepaid practice plan, and 
faculty practice plan; and e) refers to appendix 3.3. 
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Appendix 3.1. Antidepressant medications by class29 
Tricyclics (TCAs) Monoamine Oxidase Inhibitors (MAOIs) 
 
Amitriptylinea), b), f) 
  
Isocarboxazid 
 
Amoxapineb) 
 
Phenelzine 
 
Clomipraminea), b), f) 
 
Tranylcypromine 
 
Desipramineb) 
 
Rasagilinec) 
 
Doxepina), b), f) 
 
Selegilinec) 
 
Imipraminea), b), f) Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 
 
Maprotiline 
 
Desvenlafaxine 
 
Nortriptylineb) 
 
Duloxetine 
 
Protriptylineb) 
 
Levomilnaciprane) 
 
Trimipraminea), b), f) 
 
Venlafaxine 
Serotonin Modulators 
 
Milnaciprand) 
 
Nefazodone Miscellaneous 
 
Trazodone 
 
Bupropion 
 
Vilazodonee) 
 
Mirtazapine 
 
Vortioxetinee) 
 
 Selective Serotonin Reuptake Inhibitors (SSRIs) 
 
 
 
Citalopram 
 
 
 
Escitalopram 
 
 
 
Fluoxetine 
 
 
 
Fluvoxamine 
 
 
 
Paroxetineb) 
    Sertraline    
Note: a) denotes tertiary TCAs; b) denotes drugs with strong anticholinergic properties; c) denotes a MAO-B inhibitor and is primarily classified as anti-Parkinsonian agents; d) is 
primarily classified as fibromyalgia agents; e) indicates that it is not available in NAMCS; and f) indicates that it should be avoided, or potentially inappropriate, regardless of 
diagnosis, according to 2012/2015 Beers criteria.   
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Appendix 3.2. 2012/2015 Beers criteria for potentially inappropriate antidepressant use in older adults due to drug-disease or 
drug-syndrome interactions that may exacerbate the disease or syndrome5-6 
Disease or syndrome  
(ICD-9-CM code) 
Antidepressanta) Rationale Recommendation 
Quality 
of 
Evidence 
Strength of 
recommendation 
Cardiovascular           
 
Syncope  
(780.2, 992.1) 
Tertiary TCAs 
Increase risk of orthostatic hypotension or 
bradycardia 
Avoid Moderate Strong 
Central nervous system     
   
 
Chronic seizures or epilepsy  
(345, 780.33) 
bupropion;  
maprotiline 
Lowers seizure threshold; may be acceptable in 
patients with well-controlled seizures in whom 
alternative agents have not been effective 
Avoid Moderate Strong 
 
Delirium  
(290.11, 290.3, 290.41, 291.0, 
292.81, 293.0, 293.1) 
TCAs;  
Anticholinergics 
Induce or worsen delirium in older adults; if 
discontinuing drugs used chronically, taper to 
avoid withdrawal symptoms 
Avoid Moderate Strong 
 
Dementia and cognitive 
impairment  
(290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 331.0, 
331.19, 331.82, 331.83) 
Anticholinergics Avoid because of adverse CNS effects Avoid High Strong 
 
History of falls or fractures 
(E880-E888)b) 
TCAs; SSRIs 
Ability to produce ataxia, impaired psychomotor 
function, syncope, and additional falls 
Avoid unless safer 
alternatives are not 
available 
High Strong 
Gastrointestinal     
   
 
Chronic constipation  
(564) 
Tertiary TCAs; 
Anticholinergics 
Can worsen constipation 
Avoid unless no other 
alternatives 
Moderate 
to low 
Weak 
  
Lower urinary tract symptoms, 
benign prostatic hyperplasia  
(600) 
Anticholinergics 
May decrease urinary flow and cause urinary 
retention 
Avoid in men Moderate 
Inhaled agents: strong; 
others: weak 
Note: a) refers to appendix 3.1 for full description; and b) excluded in the analysis for consistency, as NAMCS only collected external cause information using ICD-9-CM in 2002-
2004.  
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Appendix 3.3. Mental health diagnosis46 
Diagnosis 
ICD-9-CM diagnostic code  
(290-319) 
Affective disorder   
 
Major depression 296.2 & 296.3 
 
Dysthymia 300.4 
 
Other affective disorder 
296.1, 296.81, 296.82, 296.9, & 
311.0 
Bipolar disorder   
 
Bipolar disorder 
296.00-296.06, 296.40-296.46, 
296.50-296.56, 296.60-296.66, 
296.7, 296.80, 296.89 
Schizophrenia   
 
Schizophrenia 295 
Delirium, dementia, and other cognitive impairment   
 
Delirium 
290.11, 290.3, 290.41, 291.0, 
292.81, 293.0, 293.1 
 
Dementia and other cognitive impairment 
290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 331.0, 
331.19, 331.82, 331.83 
Anxiety Disorders   
 
Generalized anxiety disorder (GAD) 300.02 
 
Panic disorder with or without agoraphobia 300.01 & 300.21 
 
Obsessive-compulsive disorder 300.3 
Personality Disorders   
 
Personality disorders 301 
Others Otherwise 
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Appendix 3.4. National trends of antidepressant prescriptions among older adults in 
office-based outpatient settings, 2002-2012 NAMCS. 
Year 
Overall prescription of 
antidepressants (95% CI) 
Overall potentially 
inappropriate 
prescription of 
antidepressants (95% CI) 
Potentially inappropriate use 
of  antidepressants among 
antidepressant-related visits 
(95% CI) 
2002 5.2 % (4.34, 6.27) 0.9% (0.66, 1.20) 17.0% (13.11, 21.81) 
2003 6.4% (5.30, 7.75) 0.9% (0.65, 1.33) 14.5% (10.54, 19.58) 
2004 7.1% (5.73, 8.83) 1.0% (0.62, 1.48) 13.5% (9.42, 19.00) 
2005 8.6% (7.30, 10.18) 1.5% (0.98, 2.13) 16.8% (12.27, 22.45) 
2006 8.6% (7.48, 9.90) 1.0% (0.77, 1.32) 11.7% (9.09, 14.99) 
2007 8.7% (7.50, 10.05) 1.2% (0.91, 1.57) 13.8% (10.84, 17.32) 
2008 9.9% (8.71, 11.18) 0.9% (0.63, 1.24) 9.0% (6.64, 12.05) 
2009 9.7% (8.51, 11.06) 0.6% (0.38, 0.81) 5.7% (3.99, 8.07) 
2010 9.6% (8.34, 10.95) 1.0% (0.67, 1.34) 9.9% (7.08, 13.76) 
2011 10.0% (8.73, 11.37) 1.1% (0.77, 1.60) 11.1% (7.76, 15.72) 
2012 10.1% (9.30, 11.03) 1.0% (0.85, 1.24) 10.1% (8.46, 12.11) 
Total 8.5% (8.08, 9.03) 1.0% (0.88, 1.09) 11.5% (10.51, 12.54) 
P-value <0.0001 0.0773 <0.0001 
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ABSTRACT 
Objective: To examine the impact of 2009 U.S. Preventive Services Task Force 
(USPSTF) depression screening recommendation on the following three outcomes: 
diagnoses of depression and other mood disorders; antidepressant prescriptions; and 
provision of non-pharmacological psychiatric services after controlling for covariates 
among older adults (ages 65+) in office-based outpatient primary care settings.  
 
Data Source: 2006-2012 National Ambulatory Medical Care Survey (NAMCS) data, a 
nationally representative sample of office-based outpatient primary care visits among 
older adults (n= 15,596 unweighted). 
 
Study Design: Using a multivariate difference-in-differences analysis, we estimated 
impacts of the USPSTF depression screening recommendation on aforementioned 
outcomes by comparing pre- (2006-2009) and post- (2010-2012) periods.  
 
Principal Findings: Visits associated with a diagnosis of mood disorders other than 
depression differentially decreased by 18.8 percentage points (95% CI: -31.1, -6.5; 
p=0.003). No differential impact was found in other outcomes. 
 
Conclusions: The 2009 USPSTF depression screening recommendation resulted in a 
decreased rate of diagnosing mood disorders other than depression, but had no impact on 
prescribing patterns of antidepressants and provision of non-pharmacological psychiatric 
services among older adults in office-based outpatient settings. 
 
  
Word Count: 177 
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4.1 Introduction 
In 2013, approximately 15.7 million U.S. adults ages 18 and over had at least one 
major depressive episode in the past year (Substance Abuse and Mental Health Services 
Administration 2014). In addition, 6.7% of U.S. adults experience major depressive 
disorder (hereafter referred to as depression) each year (National Institute of Mental 
Health 2015). While aging-related depression is a leading cause of disability and a major 
contributor for disease burden (World Health Organization 2015), depression and other 
related mood disorders (e.g., dysthymia) are often under-diagnosed and under-treated 
among adults ages 65 and over (hereafter referred to as older adults) (Wiese 2011). While 
adults with depression are not likely to make psychiatry-related visits, they still seek care 
in primary care or other specialty visits, making “these visits particularly important 
opportunities to detect and initiate treatment of depression” (Palmer and Coyne 2003, 
p.279). In light of providing care for depression in primary care and other specialty visits, 
screening for depression has become a “prominent component of the “detect—treat—
improve” paradigm for undetected depression” since mid-1990s (Palmer and Coyne 2003, 
p.280). 
In 2002, the U.S. Preventive Services Task Force (USPSTF) recommended 
depression screening for all eligible adults (U.S. Preventive Services Task Force 2002). 
Subsequently, the 2009 USPSTF practice recommendation stated depression screening 
should be provided in eligible adults to “ensure accurate diagnosis, effective treatment 
and appropriate follow-up” related to depression and other mental health conditions (U.S. 
Preventive Services Task Force 2009; U.S. Preventive Services Task Force 2015). Unlike 
the previous 2002 version, the 2009 USPSTF guideline distinguished two different 
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recommendations: a grade B recommendation is given when staff-assisted depression 
care supports are in place, and a grade C recommendation is given when staff-assisted 
depression care supports are not present in primary care settings (U.S. Preventive 
Services Task Force 2015). Unlike the grade B recommendation, the grade C 
recommendation indicates that the USPSTF makes no recommendation for or against 
routine depression screening service, and the service may be provided based on 
professional judgment and/or patient preferences (U.S. Preventive Services Task Force 
2015). In 2016, the USPSTF disseminated its updated recommendation, which remains 
unchanged that a grade B recommendation is given regardless of staff-assisted depression 
care supports status (Siu et al. 2016; U.S. Preventive Services Task Force 2016). 
In existing literature, there are few studies that assess the policy impact of recent 
USPSTF guidelines (e.g., mammography use (Block et al. 2013) and pediatric urinalysis 
(Filice et al. 2014)). However, no study has yet assessed the impact of the 2009 
depression screening recommendation, including among older adults ages 65 and over. 
Gaps remain in our understanding of whether the 2009 depression screening 
recommendation had impacts on the following outcomes: diagnoses of depression and 
other mood disorders; overall and potentially inappropriate antidepressant prescriptions; 
and provision of non-pharmacological psychiatric services among older adults ages 65 
and over. To address these gaps, we examine the policy impacts of the 2009 USPSTF 
depression screening recommendation on the aforementioned outcomes between pre- 
(2006-2008) and post- (2010-2012) periods among older adults, who made office-based 
outpatient primary care visits. 
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4.2 Methods 
Data Source and Study Sample 
 We used data from 2006-2012 National Ambulatory Medical Care Survey 
(NAMCS), which are administrated by National Center for Health Statistics (NCHS) of 
the Centers for Disease Control and Prevention (CDC) (National Center for Health 
Statistics 2009). The NAMCS is an annual, cross-sectional survey of visits to office-
based physicians in outpatient settings, and provides reliable information about the 
provision and/or use of ambulatory medical care services in the United States (National 
Center for Health Statistics 2009). Our final analytic sample included older adults ages 65 
and over, who had primary care visits, and had completed data for all covariates 
(n=15,596 unweighted). Using publicly available data, the research procedure for this 
study was exempted from the University of Minnesota Institutional Review Board. 
Further details of the survey, including descriptions, questionnaires, sampling 
methodology and datasets, are publicly available on the NAMCS website (National 
Center for Health Statistics 2015).  
 
Measures 
Dependent variables. Three main outcomes of interests are as follow: diagnosis of mental 
health conditions, antidepressant prescription, and provision of non-pharmacological 
psychiatric services. First, we included the diagnosis of mental health conditions (i.e., 
depression only, mood disorders other than depression, and any mood disorders) (see 
Appendix 4.1 (Finkelstein, Prabhu, and Chen 2007). The NAMCS collects up to three 
clinical diagnoses using the International Classification of Diseases, 9th edition, clinical 
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modification (ICD-9-CM) diagnostic codes. We constructed three binary variables (yes or 
no/missing) for diagnosis of mental health conditions, and they are depression only, 
mood disorders other than depression, and overall, any mood disorders.  
 Second, antidepressant prescription was another outcome measure. The NAMCS 
collects up to eight medications in 2006-2011 and up to 10 medications in 2012. Using 
the 2015 American Hospital Formulary Service (AHFS) Compendium (American Society 
of Health-System Pharmacists 2015), Wolters Kluwer’s Drug Facts and Comparisons 
(Wolters Kluwer Clinical Drug Information 2015), and previous studies (Lindsey 2009; 
Mamdani et al. 2000; Maust, Oslin, and Marcus 2014; Mort and Aparasu 2000; Olfson 
and Marcus 2009; Sclar et al. 2012), we identified prescribed antidepressant medications 
using generic names (see Appendix 4.2). We constructed a binary variable (yes or no) for 
overall antidepressant prescriptions. For potentially inappropriate antidepressant 
prescriptions, we constructed a binary variable (yes or no) using the 2012/2015 Beers 
Criteria (see Appendices 4.2 and 4.3 (American Geriatrics Society Beers Criteria Update 
Expert Panel 2012, 2015)). 
 Third, we included non-pharmacological psychiatric service use as an outcome 
measure. The NAMCS asks two questions whether psychotherapy and mental health 
counseling other than psychotherapy were provided (yes or no) (National Center for 
Health Statistics 2010). Due to limited sample size, a binary variable (yes or no) was 
created aggregating these two questions.  
 
Independent variables. The key exposure of interest was the depression screening status 
(yes or no). More specifically, the NAMCS asks, “Was the depression screening exam 
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ordered or provided at the visit?” The time indicator variable was also included to 
identify before and after the 2009 USPSTF depression screening guideline (0=2006-2008 
(known as a reference category) and 1=2009-2012).  
 
Control variables. Based on previous studies (Aparasu, Jano, and Bhatara 2009; Comer, 
Mojtabai, and Olfson 2011; Daumit et al. 2002; Harrison et al. 2010; Jameson and Blank 
2010; Lagomasino, Stockdale, and Miranda 2011; Manseau and Case 2014; Maust et al. 
2014; Mojtabai and Olfson 2010; Mort and Aparasu 2000; Olfson and Marcus 2009; 
Sankaranarayanan and Puumala 2007), we identified a number of covariates. We 
included demographic variables: age (65-74, 75-84, or 85+), gender, race/ethnicity, 
region (Northeast, Midwest, South, or West), primary source of payment (Medicare, 
Medicaid, private, or others), reason for visit (acute problem, routine chronic problem, 
preventive care, or pre- or post-surgery care), and repeat of visits within the past 12 
months (none, 1-2, 3-5, or 6+). In addition, we included the following clinical 
characteristics: type of medical practice (solo or others), metropolitan statistical area 
(MSA) status (yes or no), time spent with doctor (<15, 15-20, 21-30, or >30 min.), 
number of chronic conditions (none, 1, 2-3, or 4+), and number of medications (0-2, 3-5, 
or 6+). The number of chronic conditions was based on 14 chronic conditions (yes or no) 
collected by the NAMCS (e.g., arthritis, congestive heart failure, and diabetes) (National 
Center for Health Statistics 2010). The variable, repeat of visits, had the largest missing 
proportion (14.8%), and was imputed based on age, gender and the number of 
medications using the hotdeck imputation technique (Mander and Clayton 2007). Other 
variables that had missing values included: primary source of payment (3.9%), reason for 
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visit (1.7%), and the number of chronic conditions (1.2%). Observations with all of these 
missing values (6.5%) were systematically excluded, leaving the final sample size of 
15,596 visits (unweighted).   
 
Data Analysis  
First, we examined the extent to which demographic and clinical characteristics 
differed in older adults by the depression screening status. We used cross-tabulations and 
design-based F-tests to investigate differences by the depression screening status. Second, 
we employed a series of difference-in-differences (DID) models to investigate if the 2009 
USPSTF depression screening recommendation had differential impacts on three 
aforementioned different outcomes. This was done by regressing each outcome on the 
indicator variable of depression screening status (yes or no), a time indicator variable 
(before 2009 (i.e., 2006-2008) or after 2009 (i.e., 2010-2012)), and the interaction of 
these two variables, while adjusting for all other covariates. We used Stata 13.1 
(StataCorp. 2013) for all analyses and the svy commands in Stata were employed to 
account for the complex sample design of the NAMCS (i.e., unequal probability of 
selection, clustering and stratification). 
 
4.3 Results 
Characteristics of the Study Sample 
  Table 4.1 presents demographic and clinical characteristics of older adults in 
office-based outpatient primary care visits by the depression screening status before the 
implementation of 2009 USPSTF depression screening recommendation (2006-2008). 
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All outcomes of interest had significant differences by the depression screening status 
(p<0.0001). 44.0% of older adults, who had a depression screening exam during their 
office-based outpatient primary care visits, were also diagnosed with some form of 
mental health conditions (p<0.0001). It is also noteworthy that about 30.0% of older 
adults who received a depression screening exam also had antidepressant prescriptions 
(p<0.0001). For non-pharmacological psychiatric services, 4.8% and 6.0% of older adults, 
who received the depression screening exam, had psychotherapy and mental health 
counseling other than psychotherapy, respectively (p<0.0001).  
 For demographic characteristics, age, gender, race/ethnicity, and other factors 
were not significantly differed by the depression screening status. Unlike demographic 
characteristics, however, most of clinical characteristics had significant differences by the 
depression screening status. For example, among older adults who had depression 
screening exam, the majority (95.6%) had solo as type of medical practice (p=0.0427). 
For time spent with doctor, 57.6% of older adults, who had the depression screening 
exam, spent at least 21 minutes with their doctors, and this is comparable to those who 
did not receive the depression screening exam (22.7%) (p<0.0001). For multiple chronic 
conditions, 73.7% of older adults, who received the depression screening exam, had with 
at least two conditions, which is significantly higher than those who did not receive the 
depression screening exam (67.0%) (p=0.0038). Lastly, for the number of medications 
prescribed, 78.4% of older adults, who had the depression screening exam, had at least 
three medications prescribed, and this is significantly higher than those who did not have 
the depression screening exam (62.8%) (p=0.0003).    
<Table 4.1 about here> 
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Difference-in-Differences 
 Table 4.2 presents the adjusted prevalence of selected outcomes among older 
adults in their office-based outpatient primary care visits by depression screening status 
and the time period. Overall, the prevalence of diagnosis with any mood disorders 
significantly decreased from 43.6% in pre-2009 to 26.6% in post-2009 among older 
adults who had the depression screening exam in their visits. On the other hand, the 
prevalence of diagnosis with any mood disorders increased from 6.0% in pre-2009 to 7.1% 
in post-2009 among older adults who did not have the depression screening exam in their 
visits. Differences by the time period indicate that -37.6% among the pre-2009 and -19.5% 
among the post-2009, resulting in a differential impact of -18.1% (95% CI: -30.9, -5.2; 
p=0.006). According to the sub-group analysis, such differential impact is largely due to 
the diagnosis of mood disorders other than depression, which had the differential impact 
of -18.8% (95% CI: -31.1, -6.5; p=0.003), rather than depression itself (p=0.608). No 
differential impact due to the 2009 USPSTF depression screening recommendation was 
found in the cases of antidepressant prescription patterns (p=0.680) and the utilization of 
psychiatric services (p=0.679).  
<Table 4.2 about here> 
 
4.4 Discussion 
 This is one of the first population-based observational studies to examine the 
impact of the 2009 USPSTF depression screening recommendation among older adults in 
office-based outpatient settings. Overall, significant reductions were found in diagnoses 
of mood disorders other than depression and overall mood disorders. On the other hand, a 
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slight increase in the diagnosis rate of depression was found due to the depression 
screening recommendation, but it was not statistically significant. Finally, no differential 
impact was found in terms of prescribing patterns of antidepressants and provision of 
non-pharmacological psychiatric services. 
 First, an increased rate of depression diagnosis was found, while it was not 
statistically significant. This finding is consistent with previous studies that show no or 
uncertain improvement of depression-related outcomes due to depression screening 
(Thombs and Ziegelstein 2014; Thombs et al. 2014). It may be due to a broadly defined 
guideline in the USPSTF depression screening recommendation statements, which do not 
specify which depression screening instruments should be used in primary care settings. 
This implies that primary care patients may be asked as few as two questions suggested 
by Whooley and her colleagues (Whooley et al. 1997), or other comprehensive tools, 
such as a 9-item Patient Health Questionnaire (PHQ-9) (Moriarty et al. 2015; Spitzer, 
Kroenke, and Williams 1999), and Kessler psychological distress scale (Kessler et al. 
2002) among others (Bland and Streiner 2013; Maurer 2012). Due to heterogeneity of 
various depression screening tools that may be used across diverse primary care practices, 
it is possible that only a slightly increased rate, which was not statistically significant, of 
depression diagnosis was observed.  
According to the American Geriatrics Society, PHQ-2 is recommended as an 
initial depression screening tool, and a 15-item Geriatric Depression Scale as a follow-up 
test for older adults (Maurer 2012). It remains unclear whether this study’s findings 
would have been different if only these two specific instruments were used in this 
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specific population of interest. Future research needs to elucidate the roles of specific 
depression screening tools on the depression diagnosis in this specific population group.  
 Second, we found a significant decrease in the rate of diagnoses of mood 
disorders other than depression. One of possible reasons is the quality of depression 
screening tools. For example, false-positive rates of existing screening tools are relatively 
high (Bland and Streiner 2013), such that primary care providers do not order follow-up 
tests for mental health diagnoses other than depression. Alternatively, another possible 
reason is that primary care providers may not be well-informed about procedures when 
several screening tools are available with little evidence of such tools (Bland and Streiner 
2013). Future research needs to address if significant reductions in the rate of diagnosing 
mood disorders other than depression are due to selectivity of depression screening tools 
and/or practicing patterns (e.g., knowledge) among primary care providers.   
 Third, no differential impact was found for prescribing patterns of antidepressants 
and provision of non-pharmacological psychiatric services. It is not surprising given that 
no significant increase in the rate of depression diagnosis and a significant decrease in the 
rate of diagnoses of mood disorders other than depression were found in this study. Such 
a finding, however, does not endorse casual relationships among depression screening, 
diagnoses and treatments of depression and other mood disorders. Future research is 
needed to characterize casual pathways for depression screening, diagnoses and 
treatments of depression and other mood disorders; such findings can further guide the 
effectiveness of a depression screening guideline. 
The study has several limitations. First, unlike the 2002 and 2016 versions, the 
2009 USPSTF depression screening recommendation distinguishes that use of the 
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screening service is recommended if and only if staff-assisted depression care supports 
are in place (i.e., grade B recommendation). Otherwise, the screening service may only 
be provided depending on individual circumstances (i.e., grade C recommendation) (U. S. 
Preventive Services Task Force 2009). Because the NAMCS does not collect information 
regarding staff-assisted depression care supports, careful interpretations of the study 
findings are needed. In other words, the study assumes that depression screening was 
provided whether staff-assisted depression care supports were in place or not when it was 
given. Currently, no publicly available national data allow us to collect such information.  
Second, the unit of analysis in this study was patient visits, not individual patients. 
This may have resulted in differential estimates when compared to other patient-based 
studies. In addition, detailed depression screening strategies are not known in the 
NAMCS. For instance, future research should address such issues (e.g., types and 
intensity of depression screening) when examining the roles of depression screening on 
diagnosing and treating depression and other mental health conditions.    
Strengths of the study include the use of a quasi-experimental difference-in-
differences method (Khandker, Koolwal, and Samad 2010) to evaluate the impact of the 
2009 depression screening recommendation at a national level. In particular, the research 
design accounted for secular time trends in the use of depression screening and 
differential time trends in unobserved control variables (Khandker et al. 2010). This study 
adds value to existing literature because no population-based observational study was 
conducted to support previous studies, as they solely used a randomized controlled trial 
approach (O'Connor et al. 2009; Thombs et al. 2013; Thombs et al. 2014).  
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 In conclusion, the study provides pioneering evidence that the 2009 USPSTF 
depression screening recommendation resulted in a decreased rate of diagnosing mood 
disorders other than depression, but had no impact on prescribing patterns of 
antidepressants and provision of non-pharmacological psychiatric services among older 
adults in office-based outpatient settings. As for policy implications, the Canadian Task 
Force on Preventive Health Care recommended against depression screening in 2013 
because no RCT study supports the effectiveness of depression screening on depression 
outcomes in primary care settings (Thombs and Ziegelstein 2013). Currently, the 2016 
USPSTF recommendation remains unchanged in the U.S. More population-based 
observational research, which eventually overcomes current limitations, is needed in the 
near future to strengthen and support current USPSTF depression screening 
recommendation statements.  
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Table 4.1. Selected baseline characteristics (weighted percent) of older adults in 
office-based outpatient primary care settings by depression screening, 2006-2008 
NAMCS. 
    Depression screening 
Total P-value 
    No Yes 
Mental health diagnosisa) 
   
 
 
None/missing 93.8 56.0 93.1 
<0.0001 
 
Yes 6.2 44.0 6.9 
Antidepressant prescription 
    
 
No 88.5 69.9 88.1 
<0.0001 
 
Yes, appropriate 10.1 29.6 10.4 
 
Yes, potentially inappropriate 1.5 0.6 1.5 
Psychotherapy provided  
   
 
 
Yes 0.1 4.8 0.2 
<0.0001 
 
No 99.9 95.2 99.8 
Mental health counseling provided  
(excluding psychotherapy)   
 
Yes 0.4 6.0 0.5 
<0.0001 
 
No 99.6 94.0 99.5 
Age  
   
 
 
65-74 49.5 55.7 49.7 
0.4851 
 
75-84 36.9 32.6 36.8 
 
85+ 13.6 11.7 13.6 
Gender 
   
 
 
Female 59.8 63.2 59.9 
0.5555 
 
Male 40.2 36.8 40.1 
Race/ethnicity 
   
 
 
Non-Hispanic White 77.8 83.3 77.9 
0.3244 
 
Non-Hispanic Black 9.4 5.9 9.4 
 
Hispanic 8.2 9.7 8.3 
 
Othersb) 4.6 1.1 4.5 
Region 
   
 
 
Northeast 16.7 31.7 17.0 
0.0508 
 
Midwest 19.8 17.5 19.7 
 
South 43.4 44.5 43.4 
 
West 20.1 6.4 19.8 
Source of payment  
   
 
 
Private 17.1 18.1 17.2 
0.4228 
 
Medicare  75.8 78.7 75.9 
 
Medicaid 4.9 2.8 4.9 
 
Othersc) 2.1 0.3 2.1 
Reason for visit 
   
 
 
Acute problem 32.7 20.6 32.5 
0.0730 
 
Routine chronic problem 50.8 55.1 50.9 
 
Preventive care 14.1 23.9 14.3 
 
Pre- or post-surgery 2.4 0.5 2.3 
96 
 
 
  
    
Repeat of visits 
   
 
 
0 visit 2.7 4.8 2.7 
0.3260 
 
1-2 visits 23.7 27.6 23.7 
 
3-5 visits 38.8 42.7 38.9 
 
6+ visits 34.8 24.9 34.6 
Type of medical practice 
   
 
 
Solo 88.9 95.6 89.0 
0.0427 
 
Othersd) 11.1 4.5 11.0 
MSA status 
   
 
 
MSA 80.4 90.7 80.6 
0.0824 
 
Non-MSA 19.6 9.3 19.4 
Time spent with doctor 
   
 
 
< 15 min. 15.1 4.1 14.8 
<0.0001 
 
15-20 min. 62.3 38.4 61.8 
 
21-30 min. 16.0 28.1 16.2 
 
> 30 min. 6.7 29.5 7.1 
Multiple chronic conditions (MCCs) 
    
 
None 11.3 2.3 11.1 
0.0038 
 
1 21.8 23.9 21.8 
 
2-3 47.5 42.4 47.4 
 
4+ 19.5 31.4 19.7 
Number of medications 
   
 
 
0 12.0 3.2 11.8 
0.0003 
 
1-2 25.2 18.3 25.1 
 
3-5 29.1 47.2 29.4 
 6+ 33.7 31.2 33.7 
Sample size 
   
 
 
Unweighted sample 6,169 114 6,283 
  Weighted population 92,405,865 1,768,751 93,590,045  
Note: a) refers to appendix 4.1; b) includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or 
Other Pacific Islanders (NHOPI), and multiple races; c) includes worker’s compensation, self-pay, no charge, and 
others; and d) includes federally qualified health center (FQHC), non-federal government clinic, family planning clinic, 
health maintenance organization (HMO) or other prepaid practice plan, and faculty practice plan. 
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Table 4.2. Adjusted proportion of selected outcomes among older adults in office-based outpatient primary care settings by 
depression screening, NAMCS 2006-2012. 
  
With depression 
screening (%) 
  
Without 
depression 
screening (%) 
  Difference (%)   Difference-in-Differences (%) 
    
Pre-
2009 
Post-2009   
Pre-
2009 
Post-2009   
Pre-
2009 
Post-2009   b 95% CI P-value 
Mental health diagnosis  
            
 
Diagnosed with any mood 
disorder(s) 
43.6 26.6 
 
6.0 7.1 
 
-37.6 -19.5 
 
-
18.1 
(-30.9, -5.2) 0.006 
 
Diagnosed with depression 1.3 2.2 
 
0.0 0.1 
 
-1.3 -2.1 
 
0.8 (-2.1, 3.6) 0.608 
 
Diagnosed with mood 
disorders other than 
depression 
42.3 24.4 
 
6.0 6.9 
 
-36.3 -17.5 
 
-
18.8 
(-31.1, -6.5) 0.003 
Antidepressant prescription 
     
 
  
 
 
  
 
Prescribed with any 
antidepressant(s) 
28.2 25.8 
 
10.9 10.8 
 
-17.3 -15.0 
 
-2.3 (-13.1, 8.5) 0.680 
 
Prescribed with potentially 
inappropriate 
antidepressants 
0.5 -0.1 
 
1.6 1.4 
 
1.1 1.5 
 
-0.4 (-1.8, 0.8) 0.463 
Psychiatric service use 
     
 
  
 
   
  
Provided with 
psychotherapy or other 
mental health counseling 
9.1 10.9   0.4 0.4 
  
-8.7 -10.5 
  
1.8 (-6.6, 10.1) 0.679 
Sample size 
            
 
Unweighted sample 323 
 
15,273 
    
15,596 
 Weighted population 1,748,058  91,841,986     93,590,045 
Note: controlled for all other covariates. 
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Appendix 4.1. Mental health diagnosis 
Diagnosis 
ICD-9-CM diagnostic code  
(290-319) 
Affective disorder   
 
Major depression 296.2 & 296.3 
 
Dysthymia 300.4 
 
Other affective disorder 
296.1, 296.81, 296.82, 296.9, & 
311.0 
Bipolar disorder   
 
Bipolar disorder 
296.00-296.06, 296.40-296.46, 
296.50-296.56, 296.60-296.66, 
296.7, 296.80, 296.89 
Schizophrenia   
 
Schizophrenia 295 
Delirium, dementia, and other cognitive impairment   
 
Delirium 
290.11, 290.3, 290.41, 291.0, 
292.81, 293.0, 293.1 
 
Dementia and other cognitive impairment 
290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 331.0, 
331.19, 331.82, 331.83 
Anxiety Disorders   
 
Generalized anxiety disorder (GAD) 300.02 
 
Panic disorder with or without agoraphobia 300.01 & 300.21 
 
Obsessive-compulsive disorder 300.3 
Personality Disorders   
 
Personality disorders 301 
Others Otherwise 
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Appendix 4.2. Antidepressant medications by class 
Tricyclics (TCAs) Monoamine Oxidase Inhibitors (MAOIs) 
 
Amitriptylinea), b), f) 
  
Isocarboxazid 
 
Amoxapineb) 
 
Phenelzine 
 
Clomipraminea), b), f) 
 
Tranylcypromine 
 
Desipramineb) 
 
Rasagilinec) 
 
Doxepina), b), f) 
 
Selegilinec) 
 
Imipraminea), b), f) Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 
 
Maprotiline 
 
Desvenlafaxine 
 
Nortriptylineb) 
 
Duloxetine 
 
Protriptylineb) 
 
Levomilnaciprane) 
 
Trimipraminea), b), f) 
 
Venlafaxine 
Serotonin Modulators 
 
Milnaciprand) 
 
Nefazodone Miscellaneous 
 
Trazodone 
 
Bupropion 
 
Vilazodonee) 
 
Mirtazapine 
 
Vortioxetinee) 
 
 Selective Serotonin Reuptake Inhibitors (SSRIs) 
 
 
 
Citalopram 
 
 
 
Escitalopram 
 
 
 
Fluoxetine 
 
 
 
Fluvoxamine 
 
 
 
Paroxetineb) 
    Sertraline    
Note: a) denotes tertiary TCAs; b) denotes drugs with strong anticholinergic properties; c) denotes a MAO-B inhibitor and is primarily classified as anti-Parkinsonian agents; d) is 
primarily classified as fibromyalgia agents; e) indicates that it is not available in NAMCS; and f) indicates that it should be avoided, regardless of diagnosis, according to 2012 
Beers criteria.   
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Appendix 4.3. 2012/2015 Beers criteria for potentially inappropriate antidepressant use in older adults due to drug-disease or 
drug-syndrome interactions that may exacerbate the disease or syndrome 
Disease or syndrome  
(ICD-9-CM code) 
Antidepressanta) Rationale Recommendation 
Quality 
of 
Evidence 
Strength of 
recommendation 
Cardiovascular           
 
Syncope  
(780.2, 992.1) 
Tertiary TCAs 
Increase risk of orthostatic hypotension 
or bradycardia 
Avoid Moderate Strong 
Central nervous system     
   
 
Chronic seizures or 
epilepsy  
(345, 780.33) 
bupropion;  
maprotiline 
Lowers seizure threshold; may be 
acceptable in patients with well-
controlled seizures in whom alternative 
agents have not been effective 
Avoid Moderate Strong 
 
Delirium  
(290.11, 290.3, 290.41, 
291.0, 292.81, 293.0, 293.1) 
TCAs;  
Anticholinergics 
Induce or worsen delirium in older 
adults; if discontinuing drugs used 
chronically, taper to avoid withdrawal 
symptoms 
Avoid Moderate Strong 
 
Dementia and cognitive 
impairment  
(290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 
331.0, 331.19, 331.82, 
331.83) 
Anticholinergics Avoid because of adverse CNS effects Avoid High Strong 
 
History of falls or fractures 
(E880-E888) 
TCAs; SSRIs 
Ability to produce ataxia, impaired 
psychomotor function, syncope, and 
additional falls 
Avoid unless safer 
alternatives are not 
available 
High Strong 
Gastrointestinal     
   
 
Chronic constipation  
(564) 
Tertiary TCAs; 
Anticholinergics 
Can worsen constipation 
Avoid unless no 
other alternatives 
Moderate 
to low 
Weak 
  
Lower urinary tract 
symptoms, benign 
prostatic hyperplasia  
(600) 
Anticholinergics 
May decrease urinary flow and cause 
urinary retention 
Avoid in men Moderate 
Inhaled agents: 
strong; others: 
weak 
Note: a) refers to appendix 4.1 for full description.  
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ABSTRACT 
 Existing literature shows mixed findings regarding the efficacy and effectiveness 
of depression screening, and relatively little is known about the effectiveness of 
depression screening among older adults in primary care visits in the U.S. This study 
examines the effects of depression screening on the three following outcomes: mood 
disorder diagnoses, overall antidepressant prescriptions, and potentially inappropriate 
antidepressant prescriptions among older adults ages 65 or older in office-based 
outpatient primary care settings. We used data from 2010-2012 National Ambulatory 
Medical Care Survey (NAMCS), a nationally representative sample of office-based 
primary care outpatient visits among older adults (n=9,313 unweighted). We employed 
an instrumental variable approach to control for selection bias in our repeated cross-
sectional population-based study. Injury prevention and stress management were selected 
as instrumental variables, as they were considered completely exogenous to outcomes of 
interests using conceptual and statistical criteria. We conducted multivariate bivariate 
probit (biprobit) regression analyses to investigate the effect of depression screening on 
each outcome, when controlled for other covariates. We found that depression screening 
was negatively associated with potentially inappropriate antidepressant prescriptions (b=-
2.17; 95% CI -2.80 – -1.53; p<0.001). However, no significant effect of depression 
screening on diagnosis of mood disorders and overall antidepressant prescriptions was 
found. Overall, depression screening had a negative effect on potentially inappropriate 
antidepressant prescriptions. Primary care physicians and other healthcare providers 
should actively utilize depression screening to minimize potentially inappropriate 
antidepressant prescriptions in older adult patients. 
 
 
  
Word Count: 233 (out of 250) 
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5.1 Introduction 
Since the mid-1990s, depression screening has been a “prominent component of 
the “detect—treat—improve” paradigm for undetected depression” in primary care 
settings.1(p.280) While community-dwelling ambulatory adults with depression are not 
likely to visit a psychiatrist for their depression or other mood disorders, they still seek 
care in primary care or other specialty visits, making “these visits particularly important 
opportunities to detect and initiate treatment of depression” or other mood disorders.1(p. 
279) In the U.S., the rate of providing depression screening in primary care and other 
specialty visits remains relatively low; a recent study using national data suggests that 
approximately 5% of all visits had depression screening among adults ages 18 or over in 
2006-2010.2  
Since late 1990s, the U.S. Preventive Services Task Force (USPSTF), as part of 
the Agency for Healthcare Research and Quality (AHRQ), have put significant efforts to 
creating and disseminating depression screening guidelines.3 In 2002, the USPSTF 
recommended depression screening for all eligible adults (i.e., a grade B 
recommendation), indicating that clinicians should routinely screen for depression 
because there is at least fair evidence of depression screening that “improves important 
health outcomes and [such] benefits outweigh harms.”3(p. 763) Such a key recommendation 
has remained stable in updated USPSTF statements over time in 2009 and 2016.4,5 
Despite clinical and policy efforts, the utility of depression screening is 
controversial in existing literature. As summarized in Mojtabai’s work,6 advocates of 
depression screening highlight that depression screening should be used as the rates of 
detection and treatment of depression are relatively low given that the prevalence of 
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depression and other mood disorders remains high among ambulatory adults. Critics, on 
the other hand, suggest that false-positive rates of depression screening are high, such 
that depression screening is not a cost-effective approach.6-11 While existing evidence 
supports promising efficacy of depression screening in primary care settings, most of 
these studies were randomized controlled trials (RCTs) or systematics reviews from these 
RCTs.7,10 
Unlike RCTs, which emphasize efficacy in ideal settings, population-based 
observational studies can evaluate the effectiveness of depression screening with greater 
validity in real-world settings.12 To our knowledge, only one observational study had 
been conducted to describe the effect of depression screening on diagnosing and treating 
mood disorders.6 The study suggests that depression screening was negatively associated 
with antidepressant prescriptions without a diagnosis of mood disorder.6 The study, 
however, focused on the general U.S. population, and did not address potentially 
inappropriate antidepressant prescriptions in older adult populations.6  
In the U.S., an inventory of potentially inappropriate medications for older adults 
was created by Beers and his colleagues (hereafter referred to as Beers criteria) in the 
early 1990s,13 and the Beers criteria has been updated over time.14,15 Using the updated 
Beers criteria, a recent study estimated that 30.9% of older adults are exposed to 
potentially inappropriate medications.16 This is a public health issue that impacts 
potentially avoidable healthcare expenditures,17-19 increased hospitalization,20-24 
morbidity25 and mortality23 rates. In light of clinical efforts to minimize potentially 
inappropriate prescriptions, we hypothesize that depression screening may help avoid the 
prescribing of potentially inappropriate antidepressant medications in older adults. To 
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address these gaps, our study examines whether or not depression screening has potential 
effects on diagnosing and treating mood disorders among older adults who made office-
based primary care outpatient visits.  
 
5.2 Methods 
Data Source and Study Sample 
 We used data from 2010-2012 National Ambulatory Medical Care Survey 
(NAMCS) (n=138,431 unweighted), which is administrated by National Center for 
Health Statistics of the Centers for Disease Control and Prevention (CDC),26 The 
NAMCS is an annual cross-sectional survey of visits to office-based physicians in 
outpatient settings, and provides reliable information about the provision and/or use of 
ambulatory medical care services in the United States.26 Our final analytic sample 
included older adults ages 65 and over, who had primary care visits, and had completed 
data for all covariates (n=9,313 unweighted). Exclusion criteria were individuals ages 64 
or younger (n=100,314 unweighted), and had visits other than primary care visits (i.e., 
specialty visits) (n=28,105 unweighted). This study was deemed exempt by the 
University of Minnesota Institutional Review Board, as we used publicly available de-
identified data. Further details of the survey, including descriptions, questionnaires, 
sampling methodology and datasets, are publicly available on the NAMCS website.27  
 
Measures 
Dependent variables. Three main outcomes of interests were: diagnosis of mood 
disorders, antidepressant prescriptions, and potentially inappropriate antidepressant 
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prescriptions. First, we included the diagnosis of mood disorders (e.g., major depression, 
bipolar disorders, and other affective disorders) (see Appendix 5.1).28 The NAMCS 
collects up to three clinical diagnoses using the International Classification of Diseases, 
9th edition, clinical modification (ICD-9-CM), and a binary variable (yes or no/missing) 
was constructed for the diagnosis of mood disorders (see Appendix 5.1).  
For antidepressant prescriptions as an outcome measure, the NAMCS collects up 
to eight medications in 2010-2011, and up to 10 medications in 2012. For consistency 
across data, we only included the first eight medications. Using the 2015 American 
Hospital Formulary Service (AHFS) Compendium,29 Wolters Kluwer’s Drug Facts and 
Comparisons,30 and previous studies,31-36 we identified prescription-based antidepressant 
medications using generic names (see Appendix 5.2). We constructed a binary variable 
(yes or no) for overall antidepressant prescriptions. For potentially inappropriate 
antidepressant prescriptions, we constructed a binary variable (yes or no) using the 
2012/2015 Beers Criteria (see Appendices 5.2 and 5.3).14,15 
 
Independent variable. The key independent variable in this study was depression 
screening status (yes or no). The NAMCS specifically asks the following question, “Was 
the depression screening exam ordered or provided at the visit?”  
 
Instrumental variables. We included two instrumental variables, injury prevention and 
stress management. The NAMCS asks, “Was health education related to [injury 
prevention or stress management] ordered or provided at the visit?” These instrumental 
variables were binary (yes or no) in nature. The selection of these instrumental variables 
108 
 
was based on both conceptual and statistical criteria. Conceptually, the selected 
instrumental variables reflect either “the physician’s greater opportunities to assess and to 
counsel on preventive health issues”6(p.466) or “[indication of] working in practice settings 
that encourage or require more detailed and extensive preventive interventions and 
patient education.”6(p. 466) In such cases, provision of health education related to injury 
prevention and/or stress management seems highly correlated with depression screening 
as part of preventive care. It is also argued that injury prevention and/or stress 
management are completely exogenous to outcomes of interests because such preventive 
care may lead to better diagnoses of mental health conditions and/or appropriate use of 
antidepressants. Statistically, using bivariate analyses, these instrumental variables were 
adequate as they were significantly associated with the depression screening, but not with 
the outcomes of interests (p<0.05). 
 
Control variables. Based on previous studies,31,34,35,37-45 we included a number of 
covariates. For demographics, we included: age (65-74, 75-84, or 85+), gender, 
race/ethnicity, census region, primary source of payment (Medicare, Medicaid, private, or 
others), reason for visit (acute problem, routine chronic problem, preventive care, or pre-
/post-surgery care), and repeat of visits within the past 12 months (none, 1-2, 3-5, or 6+). 
We included the following clinical characteristics: type of medical practice (solo or 
others), metropolitan statistical area (MSA) status, which describes high population 
density (yes for “one or more counties that contain a city of 50,000 or more inhabitants, 
or contain a Census Bureau-defined urbanized area and have a total population of at least 
100,000 (75,000 in New England)” or no for otherwise),46 time spent with doctor (<15, 
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15-20, 21-30, or >30 min.), number of chronic conditions (none, 1, 2-3, or 4+),47 and 
number of medications (0-2, 3-5, or 6+). We also included non-pharmacological 
psychiatric service use (yes or no), as the NAMCS asks two questions whether 
psychotherapy and mental health counseling other than psychotherapy were provided or 
ordered at the visit. The variable, repeat of visits in the past 12 months, had the largest 
missing proportion (31.9%), and was imputed based on age, gender and the number of 
medications using the hotdeck imputation technique.48 Other variables that had missing 
values were: primary source of payment (4.3%), reason for visit (1.3%), and the number 
of chronic conditions (1.2%). Observations with all of these missing values (n=699 
unweighted) were systematically excluded, leaving the final sample size of 9,313 visits 
(unweighted).   
 
Data Analysis  
First, we examined the extent to which demographic and clinical characteristics 
differed by depression screening status in older adults. We used design-based F-tests to 
investigate such differences. We also estimated the prevalence of mood disorder 
diagnoses and antidepressant prescriptions by depression screening in our analytic sample.  
Second, we conducted two different regression analyses: naïve probit and 
bivariate probit (biprobit) models, for each outcome of interests.6,49 In naïve probit 
models, the issue of endogeneity of depression screening (i.e., selection bias) was ignored 
such that we regressed each outcome on depression screening while controlled for 
covariates. Each biprobit model, on the other hand, comprises of two-part models that 
adjusts for endogeneity issue of depression screening. In each biprobit model, the first 
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part has depression screening as an outcome variable, and regressed it on two 
instrumental variables, while controlling for other covariates. Then, in the second part 
model, we regressed each outcome of interests on the first part of the model, while 
controlling for covariates, respectively. The biprobit models approach was considered 
appropriate after testing for issues related to endogeneity and overidentification. After 
running the biprobit models, we only interpreted the final models (i.e., after second part) 
as the interpretations are similar to those of naïve probit models. This makes 
interpretations comparable where naïve probit models ignored the endogeneity issue (i.e., 
selection bias), and biprobit models adjusted for endogeneity and overidentification 
issues. Stata 13.150 was used for all analyses and the svy commands in Stata were 
employed to account for the complex sample design of the NAMCS (i.e., unequal 
probability of selection, clustering and stratification).  
 
5.3 Results 
Characteristics of the Study Sample 
Table 5.1 shows demographic and clinical characteristics of older adults in office-
based primary care outpatient settings by the depression screening status. In demographic 
characteristics, reason for visits and MSA status were significantly different by the 
depression screening status. For example, 76.2% of those with screened visits had routine 
chronic problems or preventive care as primary reasons for visits, which was significantly 
higher than that of non-screened visits (65.7%) (p=0.023). 90.2% of those with screened 
visits were located in MSAs, whereas 79.5% of non-screened visits were located in 
MSAs (p=0.009). 
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We found significant differences in all clinical characteristics. For instance, 86.7% 
of screened visits involved two or more multiple chronic conditions, which was 
significantly higher than that of non-screened visits (71.0%) (p<0.001). Similarly, 76.8% 
of screened visits had three or more medications prescribed, which was significantly 
higher than that of non-screened visits (67.5%) (p=0.038). Non-pharmacological 
psychiatric services were more commonly provided in screened visits (11.1%) than those 
in non-screened visits (0.5%) (p<0.001). Similarly, health education related to injury 
prevention and stress management were more commonly provided in screened visits than 
those in non-screen visits (p<0.001).  
<Table 5.1 about here> 
Depression screening was conducted in 209 out of 9,313 visits (unweighted) by 
primary care office-based physicians. As shown in both Table 5.1 and Figure 5.1, 
diagnosis of mood disorders and antidepressant prescriptions were significantly differed 
by depression screening (p<0.001). For example, 15.5% of visits with depression 
screening had both mood disorders diagnosed and antidepressants prescribed, which was 
at least five times larger than those in visits without depression screening. Furthermore, 
26.3% of visits with depression screening had either mood disorders diagnosed or 
antidepressants, and this was almost twofold higher than that of visits without depression 
screening (p<0.001). Overall, higher rates of diagnosis of mood disorders and 
antidepressant prescriptions were observed in visits with depression screening, when 
compared to visits without depression screening.  
<Figure 5.1 about here> 
Multivariate naïve and probit analyses 
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 Table 5.2 presents naïve and biprobit models with diagnosis of mood disorders as 
the primary outcome of interest. In the naïve probit model, depression screening was 
positively associated with the diagnosis of mood disorders when controlled for other 
covariates (b=0.69; 95% CI 0.41–0.98; p<0.001). In the biprobit model, depression 
screening was significantly associated with two instrumental variables, injury prevention 
and stress management, (p=0.002, respectively) in the first part model. When this first 
part model was applied in the second part model, depression screening was no longer 
significantly associated with the diagnosis of mood disorders while the relationship was 
still positive (b=1.08; 95% CI -0.13–2.30; p=0.080).  
<Table 5.2 about here> 
 Table 5.3 shows naïve and biprobit models, where the variable, antidepressant 
prescriptions, was the primary outcome of interest. The diagnosis of mood disorders was 
controlled for among other covariates. Depression screening was positively associated 
with the antidepressant prescriptions, holding other variables constant, in the naïve probit 
model (b=0.37; 95% CI 0.09–0.64; p=0.010). In the first part model of the biprobit model, 
depression screening was positively associated with both instrumental variables, injury 
prevention and stress management (p=0.005 and p=0.002, respectively). When this first 
part model was applied to the second part model in the biprobit model, depression 
screening was no longer significantly associated with the antidepressant prescriptions, 
while magnitude was even larger and the relationship was still positive (b=0.96; 95% CI -
0.59–2.51; p=0.225).    
<Table 5.3 about here> 
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 Table 5.4 presents naïve and biprobit models with the outcome of potentially 
inappropriate antidepressant prescriptions. Other covariates, including the diagnosis of 
mood disorders, were controlled for in both models. Unlike previous models (see Tables 
5.2 and 5.3), depression screening was negatively associated with the potentially 
inappropriate antidepressant prescriptions in the naïve probit model (b=-0.95; 95% CI -
1.46 – -0.44; p<0.001). In the first part model of the biprobit models, depression 
screening was positively associated with two instrumental variables, injury prevention 
and stress management (p=0.005 and p=0.001, respectively), which are consistent with 
previous models (see Tables 5.2 and 5.3). When this first part model was applied in the 
second part model of the biprobit model, depression screening was negatively associated 
with the potentially inappropriate antidepressant prescriptions (b=-2.17; 95% CI -2.80 – -
1.53; p<0.001).  
<Table 5.4 about here> 
 
5.4 Discussion 
 This is the first population-based observation study to investigate effects of 
depression screening on diagnosis of mood disorders, overall antidepressant prescriptions, 
and potentially inappropriate antidepressant prescriptions among older adults in office-
based primary care outpatient visits, using an instrumental variable approach. When 
controlling for a 2009 USPSTF depression screening guideline recommendation,51 our 
study suggests that no effect of depression screening on diagnosis of mood disorders and 
overall antidepressant prescriptions was found. However, a negative effect of depression 
screening on potentially inappropriate antidepressant prescriptions was found. 
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 First, using naïve probit models, depression screening was positively associated 
with diagnosis of mood disorders and overall antidepressant prescriptions. The 
significance of positive associations in these models disappeared when the instrumental 
variable approach was applied. Furthermore, the significance of clinical characteristics 
that had differed by depression screening using the naïve probit model disappeared in the 
biprobit models. Such findings and patterns are consistent with a previous study.6 Our 
findings, however, are in contrast with several RCT studies, which showed promising 
evidence of the role of depression screening in these outcomes.6,7,52 As suggested by 
Mojtabai,6 depression and other mood disorders detected by depression screening may be 
less severe, such that physicians and other healthcare providers (e.g., physician assistants) 
may be less likely to diagnose and treat depression and other mood disorders, when using 
the depression screening measures alone.7 An alternative explanation is that in RCT 
studies, certain depression screening tools were systematically used and tested for their 
efficacy under ideal settings. In the real world, no specific depression screening tool has 
been specifically recommended for this population of interest.53 If primary care 
physicians and other healthcare providers are not well-informed about depression 
screening tools and their utilities, they may not likely diagnose and treat depression and 
other mood disorders. Future research should elucidate discrepancies in findings from 
RCTs and population-based observational studies.   
 Second, using both naïve probit model and biprobit model, depression screening 
was negatively associated with potentially inappropriate antidepressant prescriptions, 
implying that depression screening is effective in reducing potentially inappropriate 
antidepressant prescriptions. Considering that visits with depression screening—
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compared to those without depression screening—had higher rates of diagnosis of mood 
disorders and overall antidepressant prescriptions (see Figure 5.1), physicians and other 
healthcare providers who use depression screening may also be more sensitive to clinical 
guidelines, such as Beers Criteria,15 to minimize potentially inappropriate medications. 
Future research should address this speculation to better understand the potential role of 
depression screening on potentially inappropriate antidepressant prescriptions.  
 Our findings have several policy and clinical implications. First, considering that 
the rate of antidepressant prescriptions has dramatically increased in the past decade,54 
there are increasing concerns about potentially inappropriate antidepressant use. For 
example, one study indicates that approximately one in 10 antidepressant-related visits, 
regardless of physician specialties, is exposed to potentially inappropriate antidepressant 
prescriptions in older adults. Another study51 revealed that the 2009 USPSTF depression 
screening recommendation resulted in no impact on prescribing patterns of 
antidepressants. Our study, however, suggests that depression screening still plays a 
significant, negative role on potentially inappropriate antidepressant prescriptions in older 
adults, and it may not be due to policy initiatives. Because our study advocates that 
depression screening works to reduce potentially inappropriate antidepressant 
prescriptions in older adults, policymakers should promote the use of depression 
screening in this population with potential revision of the guideline to boost its utility. 
For clinical practice, while practice modifications with respect to depression screening 
would require further research in the near future, primary care physicians and other 
healthcare providers should actively follow the depression screening guideline along with 
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their judgement calls to provide the best available healthcare to older adult patients in 
their visits.  
 This study has several limitations. First, the NAMCS data capture up to three 
diagnoses only in a sampled visit. Given these limited diagnoses, and considering that 
older adults often have multiple chronic conditions (see Table 5.1), it may have 
underreported potentially inappropriate antidepressant prescriptions due to drug-disease 
or drug-syndrome interactions.54 Second, in a given sampled visit with cross-sectional 
nature of survey design, the course and outcome of treatments (e.g., long-term use of 
antidepressants) cannot be assessed.6 In addition, refills of antidepressant medications 
without mental health diagnoses at each visit might have not been captured. Such issues 
might have led to underreporting of mental health diagnoses and potentially inappropriate 
antidepressant prescriptions. Findings from this study should be interpreted with these 
potential limitations. 
 Overall, this study reveals evidence that depression screening is effective in 
reducing potentially inappropriate antidepressant prescriptions among older adults in 
office-based primary care outpatient visits. Future research should address the reasons 
and rationales for such effect of depression screening.  
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Figure 5.1. Prevalence of antidepressant prescriptions and mood disorder diagnoses 
among older adults in office-based primary care outpatient settings, 2010-2012 
NAMCS. 
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Table 5.1. Selected baseline characteristics (weighted percent) of older adults in 
office-based primary care outpatient settings by depression screening, 2010-2012 
NAMCS. 
    Depression screening 
Total P-value 
    No Yes 
Sample size 
    
 Unweighted sample 9,104 209 9,313 
 
  Weighted population 91,278,108 1,727,366 93,005,474   
Age  
    
 
65-74 50.5 50.4 50.5 
0.9633 
 
75-84 35.0 36.0 35.0 
 
85+ 14.5 13.7 14.5 
Gender 
    
 
Female 56.6 61.0 56.7 
0.4471 
 
Male 43.4 39.0 43.3 
Race/ethnicity 
    
 
Non-Hispanic White 78.3 71.6 78.2 
0.1571 
 
Non-Hispanic Black 8.5 13.0 8.6 
 
Hispanic 8.3 14.2 8.4 
 
Othersa) 5.0 1.2 4.9 
Region 
    
 
Northeast 18.7 12.7 18.6 
0.0566 
 
Midwest 21.8 12.0 21.7 
 
South 35.5 48.3 35.7 
 
West 24.0 27.0 24.0 
Source of payment  
    
 
Private 14.7 14.1 14.7 
0.7435 
 
Medicare  82.4 84.0 82.4 
 
Medicaid 1.6 0.8 1.6 
 
Othersb) 1.3 1.1 1.3 
Reason for visit 
    
 
Acute problem 31.4 22.8 31.3 
0.0229 
 
Routine chronic problem 49.3 47.5 49.3 
 
Preventive care 16.4 28.7 16.6 
 
Pre- or post-surgery 2.9 1.0 2.9 
Repeat of visits 
    
 
0 visit 6.6 6.9 6.6 
0.5784 
 
1-2 visits 31.0 36.8 31.1 
 
3-5 visits 35.2 30.3 35.2 
 
6+ visits 27.2 25.9 27.1 
Type of medical practice 
    
 
Solo 89.6 87.8 89.5 
0.6558 
 
Othersc) 10.4 12.2 10.5 
MSA status 
    
 
MSA 79.5 90.2 79.7 
0.0089 
 
Non-MSA 20.5 9.8 20.3 
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Time spent with doctor 
    
 
< 15 min. 14.0 12.0 14.0 
0.0562 
 
15-20 min. 52.2 41.1 52.0 
 
21-30 min. 21.8 30.3 22.0 
 
> 30 min. 12.0 16.6 12.1 
Multiple chronic conditions (MCCs) 
    
 
None 8.9 2.7 8.8 
<0.0001 
 
1 20.1 10.6 19.9 
 
2-3 47.2 43.1 47.2 
 
4+ 23.8 43.6 24.1 
Number of medications 
    
 
0 11.3 3.1 11.1 
0.0381 
 
1-2 21.2 20.1 21.2 
 
3-5 25.9 24.0 25.8 
 
6+ 41.6 52.8 41.9 
Mood disorder diagnosisd) 
    
 
None/missing 92.7 72.9 92.4 
<0.0001 
 
Major depression 0.2 2.3 0.2 
 
Dysthymia 0.4 2.7 0.4 
 
Bipolar disorder 0.1 1.6 0.1 
 
Other affective disorder 1.6 12.7 1.8 
 
Others 5.0 7.8 5.1 
Antidepressant prescription 
    
 
No 87.6 69.8 87.2 
<0.0001 
 
Yes, appropriate 11.0 30.1 11.4 
 
Yes, potentially inappropriate 1.5 0.1 1.4 
Non-pharmacological psychiatric services  
    
 
Yes 0.5 11.1 0.7 
<0.0001 
 
No 99.5 88.9 99.3 
Injury prevention 
    
 
Yes 1.9 7.8 2.0 
0.0004 
 
No 98.1 92.2 98.0 
Stress management 
    
 
Yes 1.6 16.1 1.8 
<0.0001 
  No 98.5 83.9 98.2 
Note: a) includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders 
(NHOPI), and multiple races; b) includes worker’s compensation, self-pay, no charge, and others; c) includes federally 
qualified health center (FQHC), non-federal government clinic, family planning clinic, health maintenance organization 
(HMO) or other prepaid practice plan, and faculty practice plan; and d) refers to appendix 5.1. 
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Table 5.2. Naïve and bivariate probit analyses for diagnosis of mood disorders among older adults in office-based primary 
outpatient care settings, NAMCS 2010-2012. 
  
Naïve probit model for 
diagnosis of mood disorders 
 
Bivariate probit model 
   
Model for depression 
screening 
 
Model for diagnosis of 
mood disordersd) 
Variables (Reference group in parenthesis) b 95% CI P-value  b 95% CI P-value   b 95% CI P-value 
Depression screening (No) 
           
 
Yes 0.69 0.41 - 0.98 <0.001 
 
- - - 
 
1.08 -0.13 - 2.30 0.080 
Age (65-74)  
           
 
75-84 0.14 0.02 - 0.27 0.023 
 
0.04 -0.13 - 0.22 0.643 
 
0.14 0.02 - 0.26 0.024 
 
85+ 0.51 0.36 - 0.66 <0.001 
 
-0.04 -0.31 - 0.23 0.779 
 
0.51 0.36 - 0.66 <0.001 
Gender (Male) 
           
 
Female 0.22 0.10 - 0.33 <0.001 
 
0.08 -0.10 - 0.25 0.390 
 
0.22 0.11 - 0.33 <0.001 
Race/ethnicity (Non-Hispanic White) 
           
 
Non-Hispanic Black -0.07 -0.28 - 0.15 0.557 
 
0.12 -0.30 - 0.54 0.579 
 
-0.07 -0.29 - 0.15 0.539 
 
Hispanic -0.06 -0.26 - 0.15 0.584 
 
0.15 -0.21 - 0.52 0.418 
 
-0.06 -0.26 - 0.15 0.887 
 
Othersa) -0.24 -0.56 - 0.08 0.146 
 
-0.41 -0.88 - 0.05 0.083 
 
-0.23 -0.55 - 0.09 0.153 
Region (Northeast) 
           
 
Midwest 0.07 -0.12 - 0.26 0.46 
 
0.08 -0.24 - 0.39 0.635 
 
0.07 -0.12 - 0.26 0.454 
 
South 0.16 -0.02 - 0.33 0.085 
 
0.41 0.11 - 0.71 0.007 
 
0.15 -0.03 - 0.33 0.096 
 
West 0.18 -0.01 - 0.36 0.063 
 
0.26 -0.08 - 0.61 0.134 
 
0.17 -0.01 - 0.36 0.066 
Source of payment (Medicare) 
           
 
Private -0.04 -0.19 - 0.11 0.588 
 
-0.11 -0.40 - 0.18 0.471 
 
-0.04 -0.18 - 0.11 0.608 
 
Medicaid 0.51 0.11 - 0.90 0.011 
 
-0.32 -0.95 - 0.31 0.317 
 
0.51 0.12 - 0.90 0.011 
 
Othersb) 0.04 -0.23 - 0.32 0.751 
 
-0.50 -1.19 - 0.20 0.162 
 
0.05 -0.23 - 0.32 0.737 
Reason for visit (Acute problem) 
           
 
Routine chronic problem 0.22 0.09 - 0.35 0.001 
 
0.05 -0.18 - 0.29 0.663 
 
0.22 0.09 - 0.35 0.001 
 
Preventive care 0.04 -0.13 - 0.20 0.642 
 
-0.54 -1.24 - 0.15 0.125 
 
-0.05 -0.46 - 0.35 0.794 
 
Pre- or post-surgery -0.06 -0.46 - 0.35 0.788 
 
0.33 0.05 - 0.62 0.022 
 
0.03 -0.14 - 0.20 0.709 
Repeat of visits (None) 
           
 
1-2 visits 0.26 0.01 - 0.50 0.042 
 
-0.19 -0.49 - 0.12 0.229 
 
0.26 0.01 - 0.51 0.039 
 
3-5 visits 0.18 -0.07 - 0.43 0.159 
 
-0.15 -0.40 - 0.11 0.264 
 
0.18 -0.07 - 0.43 0.148 
 
6+ visits 0.24 0.00 - 0.49 0.049 
 
-0.34 -0.66 - -0.02 0.038 
 
0.25 0.01 - 0.49 0.044 
Type of medical practice (Solo) 
           
 
Othersc) -0.09 -0.35 - 0.16 0.476 
 
0.15 -0.19 - 0.48 0.383 
 
-0.09 -0.35 - 0.16 0.462 
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MSA status (MSA) 
           
 
Non-MSA 0.09 -0.09 - 0.27 0.319 
 
-0.39 -0.67 - -0.10 0.007 
 
0.09 -0.08 - 0.27 0.289 
Time spent with doctor (< 15 min.) 
           
 
15-20 min. 0.13 -0.05 - 0.32 0.160 
 
-0.12 -0.36 - 0.13 0.344 
 
0.13 -0.05 - 0.32 0.152 
 
21-30 min. 0.19 0.02 - 0.35 0.031 
 
0.09 -0.11 - 0.29 0.359 
 
0.18 0.01 - 0.35 0.033 
 
> 30 min. 0.20 0.01 - 0.40 0.045 
 
0.10 -0.18 - 0.38 0.488 
 
0.20 0.00 - 0.40 0.045 
Multiple chronic conditions (MCCs) 
(None) 
           
 
1 0.01 -0.20 - 0.23 0.899 
 
0.17 -0.30 - 0.64 0.486 
 
0.12 -0.21 - 0.22 0.912 
 
2-3 0.05 -0.17 - 0.27 0.638 
 
0.37 -0.10 - 0.83 0.123 
 
0.05 -0.17 - 0.27 0.661 
 
4+ 0.04 -0.20 - 0.28 0.742 
 
0.65 0.17 - 1.12 0.008 
 
0.03 -0.21 - 0.27 0.812 
Number of medications (None) 
           
 
1-2 0.10 -0.07 - 0.28 0.245 
 
0.49 0.09 - 0.89 0.017 
 
0.10 -0.08 - 0.27 0.272 
 
3-5 -0.01 -0.21 - 0.20 0.956 
 
0.45 0.07 - 0.83 0.020 
 
-0.01 -0.22 - 0.20 0.924 
 
6+ 0.11 -0.05 - 0.27 0.190 
 
0.51 0.11 - 0.90 0.012 
 
0.10 -0.06 - 0.27 0.214 
Psychiatric services (No) 
           
 
Yes 1.50 1.08 - 1.92 <0.001 
 
1.26 0.65 - 1.87 <0.001 
 
1.4 0.86 - 1.94 <0.001 
Injury prevention (No) 
           
 
Yes - - - 
 
0.64 0.23 - 1.05 0.002 
 
- - - 
Stress management (No) 
             Yes - - -  0.85 0.32 - 1.38 0.002  - - - 
Note: rho = 0.30; p<0.001. a) includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders (NHOPI), and multiple races; b) includes worker’s compensation, 
self-pay, no charge, and others; c) includes federally qualified health center (FQHC), non-federal government clinic, family planning clinic, health maintenance organization (HMO) or other prepaid 
practice plan, and faculty practice plan; and d) refers to appendix 5.1. 
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Table 5.3. Naïve and bivariate probit analyses for antidepressant prescriptions among older adults in office-based primary 
care outpatient settings, NAMCS 2010-2012. 
  
Naïve probit model for 
antidepressant 
prescriptions 
 
Bivariate probit model 
   
Model for depression 
screening 
 
Model for antidepressant 
prescriptions 
Variables (Reference group in parenthesis) b 95% CI P-value  b 95% CI P-value   b 95% CI P-value 
Depression screening (No) 
           
 
Yes 0.37 0.09 - 0.64 0.010 
 
- - - 
 
0.96 -0.59 - 2.51 0.225 
Diagnosis of mood disordersa) (No/missing) 
           
 
Yes 0.96 0.79 - 1.13 <0.001 
 
0.52 0.29 - 0.76 <0.001 
 
0.94 0.75 - 1.12 <0.001 
Age (65-74)  
           
 
75-84 -0.09 -0.20 - 0.02 0.095 
 
0.03 -0.14 - 0.21 0.711 
 
-0.09 -0.20 - 0.02 0.099 
 
85+ -0.11 -0.28 - 0.05 0.177 
 
-0.09 -0.37 - 0.18 0.507 
 
-0.11 -0.28 - 0.06 0.191 
Gender (Male) 
           
 
Female 0.21 0.10 - 0.33 <0.001 
 
0.04 -0.14 - 0.21 0.687 
 
0.21 0.10 - 0.33 <0.001 
Race/ethnicity (Non-Hispanic White) 
           
 
Non-Hispanic Black -0.43 -0.65 - -0.20 <0.001 
 
0.17 -0.23 - 0.58 0.407 
 
-0.43 -0.66 - -0.20 <0.001 
 
Hispanic -0.19 -0.35 - -0.02 0.027 
 
0.14 -0.24 - 0.51 0.474 
 
-0.19 -0.36 - -0.02 0.029 
 
Othersb) -0.24 -0.66 - 0.19 0.272 
 
-0.45 -0.89 - -0.00 0.049 
 
-0.23 -0.65 - 0.19 0.287 
Region (Northeast) 
           
 
Midwest -0.12 -0.27 - 0.03 0.125 
 
-0.05 -0.27 - 0.36 0.757 
 
-0.12 -0.27 - 0.03 0.128 
 
South 0.07 -0.08 - 0.22 0.345 
 
0.40 0.11 - 0.70 0.008 
 
0.06 -0.09 - 0.21 0.400 
 
West 0.03 -0.15 - 0.20 0.752 
 
0.25 -0.11 - 0.60 0.173 
 
0.02 -0.15 - 0.20 0.793 
Source of payment (Medicare) 
           
 
Private 0.09 -0.05 - 0.23 0.218 
 
-0.08 -0.39 - 0.23 0.616 
 
0.09 -0.05 - 0.23 0.205 
 
Medicaid 0.18 -0.07 - 0.43 0.153 
 
-0.31 -0.98 - 0.37 0.374 
 
0.19 -0.06 - 0.44 0.134 
 
Othersc) -0.00 -0.36 - 0.35 0.996 
 
-0.30 -0.83 - 0.22 0.255 
 
-0.01 -0.35 - 0.36 0.973 
Reason for visit (Acute problem) 
           
 
Routine chronic problem -0.01 -0.13 - 0.10 0.820 
 
0.07 -0.17 - 0.30 0.567 
 
-0.01 -0.13 - 0.10 0.814 
 
Preventive care -0.08 -0.21 - 0.05 0.247 
 
0.37 0.10 - 0.64 0.007 
 
0.23 -0.13 - 0.60 0.214 
 
Pre- or post-surgery 0.23 -0.13 - 0.59 0.214 
 
-0.70 -1.53 - 0.14 0.103 
 
-0.09 -0.22 - 0.04 0.188 
Repeat of visits (None) 
           
 
1-2 visits -0.04 -0.27 - 0.19 0.731 
 
-0.21 -0.54 - 0.12 0.208 
 
-0.03 -0.26 - 0.19 0.791 
 
3-5 visits 0.02 -0.22 - 0.25 0.884 
 
-0.18 -0.47 - 0.11 0.216 
 
0.02 -0.20 - 0.25 0.832 
 
6+ visits 0.13 -0.11 - 0.37 0.280 
 
-0.42 -0.78 - -0.06 0.023 
 
0.14 -0.09 - 0.37 0.229 
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Type of medical practice (Solo) 
           
 
Othersd) 0.07 -0.15 - 0.29 0.552 
 
0.14 -0.18 - 0.46 0.394 
 
0.06 -0.16 - 0.28 0.567 
MSA status (MSA) 
           
 
Non-MSA -0.06 -0.20 - 0.07 0.351 
 
-0.40 -0.70 - -0.11 0.007 
 
-0.06 -0.19 - 0.08 0.412 
Time spent with doctor (< 15 min.) 
           
 
15-20 min. -0.00 -0.14 - 0.15 0.948 
 
-0.10 -0.35 - 0.14 0.397 
 
0.01 -0.14 - 0.15 0.905 
 
21-30 min. 0.10 -0.06 - 0.27 0.202 
 
0.09 -0.12 - 0.30 0.401 
 
0.10 -0.06 - 0.26 0.213 
 
> 30 min. 0.03 -0.17 - 0.22 0.784 
 
0.08 -0.22 - 0.39 0.580 
 
0.02 -0.17 - 0.21 0.808 
Multiple chronic conditions (MCCs) (None) 
           
 
1 -0.02 -0.24 - 0.21 0.869 
 
0.19 -0.25 - 0.64 0.392 
 
-0.02 -0.25 - 0.20 0.855 
 
2-3 -0.12 -0.35 - 0.10 0.284 
 
0.38 -0.07 - 0.83 0.099 
 
-0.13 -0.35 - 0.10 0.266 
 
4+ -0.02 -0.25 - 0.21 0.861 
 
0.66 0.20 - 1.11 0.005 
 
-0.04 -0.26 - 0.19 0.761 
Number of medications (0-2) 
           
 
3-5 0.78 0.60 - 0.95 <0.001 
 
0.07 -0.19 - 0.33 0.602 
 
0.77 0.60 - 0.95 <0.001 
 
6+ 1.35 1.19 - 1.52 <0.001 
 
0.12 -0.11 - 0.36 0.303 
 
1.34 1.18 - 1.51 <0.001 
Psychiatric services (No) 
           
 
Yes 0.49 0.02 - 0.96 0.042 
 
1.07 0.46 - 1.69 0.001 
 
0.34 -0.30 - 0.97 0.299 
Injury prevention (No) 
           
 
Yes - - - 
 
0.61 0.18 - 1.03 0.005 
 
- - - 
Stress management (No) 
             Yes - - -  0.77 0.27 - 1.27 0.002  - - - 
Note: rho = 0.14; p=0.007. a) refers to appendix 5.1; b)includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders (NHOPI), and multiple races; c) includes 
worker’s compensation, self-pay, no charge, and others; and d) includes federally qualified health center (FQHC), non-federal government clinic, family planning clinic, health maintenance organization 
(HMO) or other prepaid practice plan, and faculty practice plan. 
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Table 5.4. Naïve and bivariate probit analyses for potentially inappropriate antidepressant prescriptions among older adults 
in office-based primary care outpatient settings, NAMCS 2010-2012. 
  
Naïve probit model for 
potentially inappropriate 
antidepressant prescriptions 
 
Bivariate probit model 
   
Model for depression 
screening 
 
Model for potentially 
inappropriate antidepressant 
prescriptions 
Variables (Reference group in parenthesis) b 95% CI P-value  b 95% CI P-value   b 95% CI P-value 
Depression screening (No) 
           
 
Yes -0.95 -1.46 - -0.44 <0.001 
 
- - - 
 
-2.17 -2.80 - -1.53 <0.001 
Diagnosis of mood disordersa) (No/missing) 
           
 
Yes -0.11 -0.39 - 0.18 0.469 
 
0.53 0.31 - 0.75 <0.001 
 
0.07 -0.43 - 0.57 0.772 
Age (65-74)  
           
 
75-84 -0.15  -0.37 - 0.08 0.197 
 
0.05 -0.13 - 0.22 0.585 
 
-0.12 -0.33 - 0.08 0.239 
 
85+ -0.56 -0.84 - -0.29 <0.001 
 
-0.07 -0.33 - 0.19 0.607 
 
-0.51 -0.83 - -0.18 0.002 
Gender (Male) 
           
 
Female 0.27 0.06 - 0.49 0.012 
 
0.04 -0.13 - 0.21 0.668 
 
0.25 0.04 - 0.46 0.020 
Race/ethnicity (Non-Hispanic White) 
           
 
Non-Hispanic Black -0.23 -0.64 - 0.18 0.265 
 
0.17 -0.24 - 0.58 0.419 
 
-0.16 -0.55 - 0.23 0.432 
 
Hispanic 0.00 -0.37 - 0.37 1.000 
 
0.18 -0.21 - 0.56 0.378 
 
0.04 -0.34 - 0.42 0.842 
 
Othersb) 0.39 -0.19 - 0.98 0.189 
 
-0.32 -0.82 - 0.19 0.216 
 
0.25 -0.54 - 1.05 0.532 
Region (Northeast) 
           
 
Midwest -0.17 -0.44 - 0.09 0.201 
 
0.00 -0.33 - 0.34 0.988 
 
-0.14 -0.41 - 0.12 0.293 
 
South 0.09 -0.15 - 0.33 0.485 
 
0.36 0.05 - 0.66 0.022 
 
0.16 -0.12 - 0.44 0.266 
 
West -0.16 -0.44 - 0.12 0.258 
 
0.20 -0.17 - 0.56 0.289 
 
-0.09 -0.44 - 0.27 0.636 
Source of payment (Medicare) 
           
 
Private -0.02 -0.31 - 0.27 0.893 
 
-0.10 -0.39 - 0.19 0.490 
 
-0.04 -0.31 - 0.24 0.783 
 
Medicaid 0.34 -0.19 - 0.87 0.208 
 
-0.32 -0.90 - 0.26 0.280 
 
0.22 -0.38 - 0.82 0.472 
 
Othersc) -0.14 -0.69 - 0.40 0.602 
 
-0.41 -1.08 - 0.25 0.223 
 
-0.14 -0.61 - 0.33 0.557 
Reason for visit (Acute problem) 
           
 
Routine chronic problem -0.01 -0.23 - 0.21 0.934 
 
0.06 -0.17 - 0.30 0.597 
 
0.01 -0.21 - 0.22 0.960 
 
Preventive care -0.17 -0.46 - 0.12 0.250 
 
0.36 0.09 - 0.64 0.010 
 
0.58 -0..05 - 1.22 0.073 
 
Pre- or post-surgery 0.70 0.24 - 1.15 0.003 
 
-0.48 -1.14 - 0.18 0.151 
 
-0.03 -0.43 - 0.37 0.876 
Repeat of visits (None) 
           
 
1-2 visits -0.16 -0.66 - 0.35 0.543 
 
-0.18 -0.50 - 0.13 0.257 
 
-0.18 -0.63 - 0.27 0.427 
 
3-5 visits 0.08 -0.40 - 0.56 0.743 
 
-0.15 -0.41 - 0.11 0.255 
 
0.03 -0.42 - 0.48 0.890 
 
6+ visits -0.24 -0.73 - 0.24 0.322 
 
-0.38 -0.72 - -0.05 0.026 
 
-0.29 -0.74 - 0.15 0.199 
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Type of medical practice (Solo) 
           
 
Othersd) -0.14 -0.43 - 0.15 0.355 
 
0.12 -0.21 - 0.45 0.479 
 
-0.07 -0.40 - 0.25 0.660 
MSA status (MSA) 
           
 
Non-MSA 0.14 -0.07 - 0.35 0.196 
 
-0.40 -0.68 - -0.11 0.006 
 
0.03 -0.29 - 0.35 0.840 
Time spent with doctor (< 15 min.) 
           
 
15-20 min. 0.15 -0.18 - 0.48 0.375 
 
-0.15 -0.42 - 0.11 0.265 
 
0.12 -0.17 - 0.42 0.417 
 
21-30 min. 0.22 -0.16 - 0.60 0.256 
 
0.07 -0.15 - 0.28 0.535 
 
0.23 -0.10 - 0.58 0.173 
 
> 30 min. 0.25 -0.12 - 0.62 0.187 
 
0.07 0.22 - 0.37 0.618 
 
0.24 -0.11 - 0.60 0.175 
Multiple chronic conditions (MCCs) (None) 
           
 
1 0.00 -0.36 - 0.37 0.985 
 
0.14 -0.29 - 0.57 0.527 
 
0.04 -0.31 - 0.40 0.809 
 
2-3 -0.21 -0.56 - 0.14 0.236 
 
0.33 -0.12 - 0.77 0.151 
 
-0.10 -0.55 - 0.34 0.649 
 
4+ -0.32 -0.65 - 0.02 0.067 
 
0.64 0.20 - 1.08 0.004 
 
-0.13 -0.66 - 0.40 0.634 
Number of medications (0-2) 
           
 
3-5 1.08 0.64 - 1.52 <0.001 
 
0.10 -0.16 - 0.36 0.446 
 
0.91 0.17 - 1.65 0.016 
 
6+ 1.42 1.01 - 1.84 <0.001 
 
0.13 -0.10 - 0.37 0.258 
 
1.22 0.39 - 2.05 0.004 
Psychiatric services (No) 
           
 
Yes -0.02 -0.89 - 0.86 0.972 
 
1.06 0.46 - 1.66 0.001 
 
0.55 -0.60 - 1.70 0.347 
Injury prevention (No) 
           
 
Yes - - - 
 
0.61 0.19 - 1.03 0.005 
 
- - - 
Stress management (No) 
             Yes - - -  0.75 0.32 - 1.18 0.001  - - - 
Note: rho = 0.33; p<0.001. a) refers to appendix 5.1; b)includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders (NHOPI), and multiple races; c) includes 
worker’s compensation, self-pay, no charge, and others; and d) includes federally qualified health center (FQHC), non-federal government clinic, family planning clinic, health maintenance organization 
(HMO) or other prepaid practice plan, and faculty practice plan. 
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Appendix 5.1. Mental health diagnosis28 
Diagnosis 
ICD-9-CM diagnostic code  
(290-319) 
Affective disorder   
 
Major depression 296.2 & 296.3 
 
Dysthymia 300.4 
 
Other affective disorder 
296.1, 296.81, 296.82, 296.9, & 
311.0 
Bipolar disorder   
 
Bipolar disorder 
296.00-296.06, 296.40-296.46, 
296.50-296.56, 296.60-296.66, 
296.7, 296.80, 296.89 
Schizophrenia   
 
Schizophrenia 295 
Delirium, dementia, and other cognitive impairment   
 
Delirium 
290.11, 290.3, 290.41, 291.0, 
292.81, 293.0, 293.1 
 
Dementia and other cognitive impairment 
290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 331.0, 
331.19, 331.82, 331.83 
Anxiety Disorders   
 
Generalized anxiety disorder (GAD) 300.02 
 
Panic disorder with or without agoraphobia 300.01 & 300.21 
 
Obsessive-compulsive disorder 300.3 
Personality Disorders   
 
Personality disorders 301 
Others Otherwise 
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Appendix 5.2. Antidepressant medications by class29  
Tricyclics (TCAs) Monoamine Oxidase Inhibitors (MAOIs) 
 
Amitriptylinea), b), f) 
  
Isocarboxazid 
 
Amoxapineb) 
 
Phenelzine 
 
Clomipraminea), b), f) 
 
Tranylcypromine 
 
Desipramineb) 
 
Rasagilinec) 
 
Doxepina), b), f) 
 
Selegilinec) 
 
Imipraminea), b), f) Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 
 
Maprotiline 
 
Desvenlafaxine 
 
Nortriptylineb) 
 
Duloxetine 
 
Protriptylineb) 
 
Levomilnaciprane) 
 
Trimipraminea), b), f) 
 
Venlafaxine 
Serotonin Modulators 
 
Milnaciprand) 
 
Nefazodone Miscellaneous 
 
Trazodone 
 
Bupropion 
 
Vilazodonee) 
 
Mirtazapine 
 
Vortioxetinee) 
 
 Selective Serotonin Reuptake Inhibitors (SSRIs) 
 
 
 
Citalopram 
 
 
 
Escitalopram 
 
 
 
Fluoxetine 
 
 
 
Fluvoxamine 
 
 
 
Paroxetineb) 
    Sertraline    
Note: a) denotes tertiary TCAs; b) denotes drugs with strong anticholinergic properties; c) denotes a MAO-B inhibitor and is primarily classified as anti-Parkinsonian agents; d) is 
primarily classified as fibromyalgia agents; e) indicates that it is not available in NAMCS; and f) indicates that it should be avoided, regardless of diagnosis, according to 2012 
Beers criteria.   
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Appendix 5.3. 2012/2015 Beers criteria for potentially inappropriate antidepressant use in older adults due to drug-disease or 
drug-syndrome interactions that may exacerbate the disease or syndrome14 
Disease or syndrome  
(ICD-9-CM code) 
Antidepressanta) Rationale Recommendation 
Quality 
of 
Evidence 
Strength of 
recommendation 
Cardiovascular           
 
Syncope  
(780.2, 992.1) 
Tertiary TCAs 
Increase risk of orthostatic hypotension or 
bradycardia 
Avoid Moderate Strong 
Central nervous system     
   
 
Chronic seizures or epilepsy  
(345, 780.33) 
bupropion;  
maprotiline 
Lowers seizure threshold; may be 
acceptable in patients with well-controlled 
seizures in whom alternative agents have 
not been effective 
Avoid Moderate Strong 
 
Delirium  
(290.11, 290.3, 290.41, 
291.0, 292.81, 293.0, 293.1) 
TCAs;  
Anticholinergics 
Induce or worsen delirium in older adults; if 
discontinuing drugs used chronically, taper 
to avoid withdrawal symptoms 
Avoid Moderate Strong 
 
Dementia and cognitive 
impairment  
(290, 291.2, 292.82, 294.10, 
294.11, 294.20, 294.21, 
331.0, 331.19, 331.82, 
331.83) 
Anticholinergics Avoid because of adverse CNS effects Avoid High Strong 
 
History of falls or fractures 
(E880-E888)b) 
TCAs; SSRIs 
Ability to produce ataxia, impaired 
psychomotor function, syncope, and 
additional falls 
Avoid unless safer 
alternatives are not 
available 
High Strong 
Gastrointestinal     
   
 
Chronic constipation  
(564) 
Tertiary TCAs; 
Anticholinergics 
Can worsen constipation 
Avoid unless no 
other alternatives 
Moderate 
to low 
Weak 
  
Lower urinary tract 
symptoms, benign prostatic 
hyperplasia  
(600) 
Anticholinergics 
May decrease urinary flow and cause 
urinary retention 
Avoid in men Moderate 
Inhaled agents: 
strong; others: weak 
Note: a) refers to appendix 5.1 for full description; and b) excluded in the analysis for consistency, as NAMCS only collected external cause information using ICD-9-CM in 2002-
2004.  
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CHAPTER 6 
 
 
 
Conclusion 
 
 
 
6.1 Summary of findings 
 The three essays on potentially inappropriate antidepressant use among older 
adults in their office-based outpatient visits employ three different methodological 
approaches: health services epidemiology (chapter 3), policy impact evaluation (chapter 
4), and clinical practice evaluation (chapter 5). Each essay presents its unique research 
questions with rationale (i.e., gaps in literature). Findings and implications of these essays 
are summarized in Table 6.1.  
 
6.2. Strengths and limitations 
One of strengths in these essays is the use of data from NAMCS, which provides 
a unique opportunity to explore issues surrounding overall and potentially inappropriate 
antidepressant prescriptions in a nationally-representative sample of U.S. older adults in 
office-based outpatient settings. However, using data from the NAMCS also includes 
several limitations. For example, across the three essays, one limitation is that NAMCS 
only collected up to three diagnoses in a sampled visit and it might have resulted in 
under-representation of potentially inappropriate antidepressant prescriptions. Each essay 
should be interpreted carefully with its strengths and limitations. 
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Table 6.1. Summary of findings 
Title 
 
Rationale 
 
Finding 
Chapter 3 (manuscript #1): Potentially 
Inappropriate Antidepressant Use 
among Older Adults in Office-based 
Outpatient Settings: National Trends 
from 2002 to 2012 
  A Beers criterion is continuously updated over time, 
but we do not know descriptive patterns of 
potentially inappropriate antidepressant prescriptions 
in U.S. older adults. 
 Objectives: To estimate the prevalence of two 
outcomes (i.e., overall and potentially inappropriate 
antidepressant prescriptions), and to investigate 
demographic and clinical factors associated with 
these outcomes among adults ages 65 and older in 
their office-based outpatient visits.  
  The prevalence of overall antidepressant 
prescriptions increase almost twofold from 5.2% in 
2002 to 10.1% in 2012. 
 About one in 10 older adults with antidepressant-
related visits are exposed to the potentially 
inappropriate antidepressant prescriptions. 
 Amitriptyline and doxepin are accounted for more 
than 70% of potentially inappropriate 
antidepressants.  
 Conclusion: Potentially inappropriate 
antidepressant prescriptions remain a serious 
problem in office-based outpatient visits. Efforts to 
minimize potentially inappropriate antidepressant 
use are needed by targeting specific disease-
independent antidepressant agents (e.g., 
amitriptyline and doxepin).   
     
Chapter 4 (manuscript #2): Impacts of 
the 2009 USPSTF Depression 
Screening Recommendation: A 
Difference-in-Differences Analysis 
  In primary care settings, depression screening is 
provided to detect and treat untreated depression and 
other related mood disorders. The United States 
Preventive Services Task Force (USPSTF) updated 
its depression guideline in 2009, but relatively little 
is known about its impact on outcomes (see below) 
among older adults in office-based primary care 
outpatient settings. 
 Objectives: To examine the impact of the 2009 
USPSTF depression screening recommendation on 
the following outcomes: diagnoses of depression and 
other mood disorders; antidepressant prescriptions; 
and provision of non-pharmacological psychiatric 
services among older adults ages 65 and over in their 
office-based primary care outpatient visits. 
  Prevalence of visits associated with the diagnosis 
of mood disorders other than depression 
differentially decreased by 18.8 percentage points 
(95% CI: -31.1, -6.5; p=0.003). 
 No differential impact was found in other 
outcomes. 
 Conclusion: The 2009 USPSTF depression 
screening recommendation resulted in a decreased 
rate of diagnosing mood disorders other than 
depression, but had no impact on prescribing 
patterns of antidepressants or provision of non-
pharmacological psychiatric services among older 
adults ages 65 and over in their office-based 
primary care outpatient visits.  
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Title 
 
Rationale 
 
Finding 
Chapter 5 (manuscript #3): Effects of 
Depression Screening on Diagnosing 
and Treating Mood Disorders among 
Older Adults in Office-based Primary 
Care Outpatient Settings: An 
Instrumental Variable Analysis 
   The 2009 USPSTF depression screening 
recommendation had no impact on potentially 
inappropriate antidepressant prescriptions (see 
Chapter 4). It is of question if depression screening 
should still be provided in clinical practice in 
primary care settings.  
 Objectives: To examine the effects of depression 
screening on three outcomes: diagnosis of mood 
disorders, overall antidepressant prescriptions, and 
potentially inappropriate antidepressant 
prescriptions, when controlled for policy initiative 
(i.e., post-2009 USPSTF depression screening 
recommendation era) and other covariates.  
   No significant effect of depression screening on 
diagnosis of mood disorders or overall 
antidepressant prescriptions was found. 
 Depression screening was negatively associated 
with potentially inappropriate antidepressant 
prescriptions (B=-2.17; 95% CI: -2.80, -1.53; 
p<0.001).  
 Conclusion: Using an instrumental variable 
technique, which accounts for omitted variable 
bias and over-identification issues, depression 
screening had a negative effect on potentially 
inappropriate antidepressant prescriptions. While 
both policy and practice modifications with respect 
to depression screening would require further 
research, primary care healthcare providers should 
actively utilize depression screening along with 
their judgment calls to provide the best available 
mental health care to older adult patients in their 
visits. 
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6.3. Future research  
 The ultimate goal of this project is to bring positive impact by promoting clinical 
and policy efforts to improve patient safety in older adults who are prescribed with 
antidepressants in office-based outpatient settings. As shown in chapter 3, potentially 
inappropriate antidepressant prescriptions remain a serious problem in office-based 
outpatient visits. Because amitriptyline and doxepin are two disease- or syndrome-
independent agents that together accounted for more than 70% of potentially 
inappropriate antidepressant prescriptions, practice interventions for minimizing the use 
of these two antidepressant agents should be considered for older adult patients in office-
based outpatient settings.  
 In addition, depression screening was found to have promising impacts on 
potentially inappropriate antidepressant prescriptions, as shown in chapters 4 and 5.  
According to findings from chapter 4, which focuses on policy impact evaluation, no 
impact of depression screening on potentially inappropriate antidepressant prescription 
was found due to the 2009 USPSTF depression screening initiative. Unlike this finding, 
however, depression screening was negatively associated with potentially inappropriate 
antidepressant prescriptions in clinical practice evaluation. These findings suggest that 
while both policy and practice modifications with respect to depression screening would 
require further research (e.g., standardization of depression screening tools for older adult 
patients), primary care healthcare providers should actively utilize depression screening 
along with their judgment calls to provide the best available mental health care to older 
adult patients in their primary care visits. 
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